COG4-Congenital Disorder of Glycosylation

👪

Inheritance

1

Autosomal Recessive HP:0000007

Biallelic COG4 variants cause the recessive disorder. Reported configurations include missense/deletion, nonsense/missense and homozygous splice-altering genotypes. A de novo allele can occur as one member of a recessive compound-heterozygous genotype; this differs from the dominant p.Gly516Arg mechanism of Saul-Wilson syndrome. When both parents carry a pathogenic recessive allele, standard Mendelian counseling gives each pregnancy a 25% affected, 50% carrier and 25% unaffected noncarrier probability. This assumes confirmed parental carrier status; the reported de novo compound-heterozygous configuration requires family-specific assessment.

Autosomal recessive inheritance

Show evidence (3 references)

PMID:42202558 SUPPORT Human Clinical

"Exome sequencing identified the homozygous COG4 c.1647+5G>A variant in four affected individuals from two apparently unrelated Italian families."

Documents homozygous inheritance of a single COG4 allele in four affected individuals across two families, establishing the recessive mode.

PMID:34298581 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"The first variant was inherited from her father, and the second was inherited from her mother."

The preceding case description identifies COG4 p.Glu419Ter and p.Cys314Tyr in patient P21, with segregation establishing opposite parental origins.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/ SUPPORT INDIRECT REVIEW SYNTHESIS Other

"At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic ... carrier ... and a 25% chance of being unaffected and not a carrier."

General autosomal-recessive counseling from the retired overview, applicable to COG4 families when both parents are carriers; not an unconditional recurrence estimate for a de novo allele.

?

Discussions and Knowledge Gaps

4

Which glycoproteins and tissue processes connect COG4 dysfunction to neurological and hepatic disease?

KNOWLEDGE GAP cog4cdg_glycan_to_organ_gap

Attached to

pathophysiology#Biallelic COG4 dysfunction pathophysiology#Abnormal N-glycan processing pathophysiology#Abnormal O-glycan processing

Clinical outcome edges have unknown intermediates. Mild or initially normal serum N-glycan assays can accompany severe disease, and the cited studies do not identify a single glycoprotein lesion explaining the organ pattern.

How do genotype and cellular background determine COG-complex abundance and Golgi morphology?

KNOWLEDGE GAP cog4cdg_conflicting_subunit_effects

Attached to

pathophysiology#Reduced COG4 Expression pathophysiology#Altered Golgi ultrastructure

The two founding patient-cell studies differ in effects on other COG subunits. Engineered p.Arg729Trp cells retain normal COG4 levels and Golgi morphology. These observations may reflect allele dosage, expression system or cellular background; they do not establish a universal isolated quantitative lesion.

Does altered autophagy contribute to recessive COG4-CDG?

KNOWLEDGE GAP cog4cdg_autophagy_hypothesis

Attached to

pathophysiology#Biallelic COG4 dysfunction

A pooled all-COG-CDG phenotype study proposed an autophagy connection to episodic fever. It did not demonstrate reduced autophagic flux or a fever mechanism in COG4 patients. Pooled phenotype frequencies and specificity rankings cannot establish COG4-specific rates.

Show evidence (1 reference)

PMID:31804708 SUPPORT INDIRECT PRIMARY RESULT Other

"The links between episodic fever and autophagy, and autophagy and the COG complex suggest that episodic fever in COG‐CDG patients, unlike other COG‐CDG phenotypic features caused by the disrupted glycosylation process, might be caused by disruption of its function in the autophagy pathway. The..."

The authors explicitly identify the autophagy-fever account as an unresolved hypothesis.

How much residual COG4 function is required for survival?

KNOWLEDGE GAP cog4cdg_residual_function

Attached to

pathophysiology#Biallelic COG4 dysfunction

A historical lobe A mutation-spectrum analysis proposed that near-total loss might be nonviable. The later homozygous splice variant produces a frameshifted transcript, but the available RNA result does not quantify residual functional protein. Neither study establishes complete-null human viability or a general prognostic rule.

Show evidence (2 references)

PMID:28848061 SUPPORT INDIRECT REVIEW SYNTHESIS Human Clinical

"This represents a frequency gap which suggests that bi-allelic truncating mutations in COG lobe A genes might be non-viable."

Mutation-spectrum hypothesis across lobe A genes; not a direct COG4 viability experiment.

PMID:42202558 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Whole transcriptome sequencing and reverse transcriptase PCR from peripheral blood detected an aberrant COG4 transcript which features skipping of exon 12 and results in a frameshift, predicted to introduce a premature termination codon."

Measured aberrant transcript with predicted premature stop, without a cited protein-null assay.

⚙

Pathophysiology

7

Biallelic COG4 dysfunction

Biallelic deleterious COG4 variants impair the function of this Golgi tethering-complex subunit. Alleles can reduce protein abundance or alter function while retaining complex assembly; the homozygous splice allele produces an aberrant transcript.

COG4 hgnc:18620

Animal models

cog4 b1312 homozygous null Danio rerio Danio rerio perturbs

Downstream

Reduced COG4 Expression

Altered Golgi ultrastructure

Global developmental delay Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Secondary microcephaly Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Brain atrophy Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Seizure Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Abnormality of coagulation Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Abnormality of the liver Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Recurrent infections Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Abnormal facial shape Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Absent speech Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Hypotonia Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Failure to thrive Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Cirrhosis Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Elevated hepatic transaminase Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Thrombocytopenia Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Hyperreflexia Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Ataxia Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Hepatic failure Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Status epilepticus Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.

Frontotemporal cerebral atrophy

Limb hypertonia

Axial hypotonia

Cognitive impairment

Show evidence (2 references)

PMID:42202558 SUPPORT DIRECT BACKGROUND Human Clinical

"is caused by biallelic deleterious variants in COG4, which encodes a component of the conserved oligomeric Golgi complex lobe A."

Establishes the causal gene and recessive disease context.

PMID:42202558 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Whole transcriptome sequencing and reverse transcriptase PCR from peripheral blood detected an aberrant COG4 transcript which features skipping of exon 12 and results in a frameshift, predicted to introduce a premature termination codon."

Direct RNA evidence for one disease-associated genotype.

Reduced COG4 Expression

Reduced COG4 protein is documented in patient fibroblasts. In the founding p.Arg729Trp/deletion case, COG4-containing complexes still assembled at reduced abundance and several other subunit levels were affected. The p.Glu233Ter/p.Leu773Arg case showed reduced COG4 with other subunits unaffected. These are genotype- and system-specific observations, not a universal absence of complex assembly.

COG4 hgnc:18620

Downstream

Delayed Golgi retrograde transport

Show evidence (2 references)

PMID:19494034 SUPPORT In Vitro

"The resulting downregulation of COG4 expression additionally affects expression or stability of other lobe A subunits."

Reduced COG4 and additional lobe A subunit effects were observed in the founding patient fibroblasts.

PMID:21185756 SUPPORT In Vitro

"As a result, COG4 protein expression was dramatically reduced, while expression of the other subunits remained unaffected."

A different patient genotype showed isolated COG4 reduction; the studies need not represent a biological contradiction.

Delayed Golgi retrograde transport

Patient fibroblasts show delayed Brefeldin A-induced redistribution of Golgi proteins to the endoplasmic reticulum. This assay supports impaired retrograde trafficking but does not directly measure every intra-Golgi tethering step. In the founding patient, Golgi reassembly after BFA washout was not delayed.

fibroblast CL:0000057

retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum GO:0006890 ↓ DECREASED

Experimental models

COG4-CDG patient fibroblasts PRIMARY CELL CULTURE

Downstream

Proposed altered Golgi enzyme recycling

Show evidence (1 reference)

PMID:21185756 SUPPORT In Vitro

"Importantly, patient fibroblasts exhibited a delay in Brefeldin A (BFA) induced retrograde transport, a common characteristic seen in COG deficiencies."

The direct cell-based measurement of the transport delay in patient material.

Proposed altered Golgi enzyme recycling

Mechanism confidence: Hypothetical

Altered localization or residence time of glycosyltransferases and/or nucleotide-sugar transporters is proposed to explain abnormal glycan processing. In the 2011 patient, Core2 transferase localization was a mechanistic interpretation of glycan products, not a direct localization measurement.

Downstream

Abnormal N-glycan processing

Abnormal O-glycan processing

Show evidence (1 reference)

PMID:21185756 SUPPORT INDIRECT PRIMARY RESULT In Vitro

"COG4 deficiency in the patient fibroblasts might affect cellular localization as well as residence time of Core2 β1,6-GlcNAc transferase with protein cargo which could lead to decreased Core2 and more Core1 glycans."

Explicitly proposed explanation for the O-glycan product distribution.

Abnormal N-glycan processing

Golgi N-glycan processing can be abnormal, with reduced terminal sialylation and galactosylation in patient serum and increased mannose-binding lectin signal in engineered p.Arg729Trp cells. These findings vary by assay and genotype: two adult COG4 patients had initially normal second-line N-glycosylation analyses.

protein N-linked glycosylation GO:0006487 ⚠ ABNORMAL

Experimental models

COG4-knockout RPE1 and HEK293T cells complemented with p.Arg729Trp CELL LINE p.Arg729Trp cells show increased GNL binding consistent with abnormal N-glycosylation.

Show evidence (3 references)

PMID:21185756 SUPPORT DIRECT BACKGROUND Human Clinical

"Analysis of serum N-glycans revealed deficiencies in both sialylation and galactosylation."

Patient serum glycan finding.

PMID:42202558 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling of serum N-glycans showed mildly deficient galactosylation and sialylation, consistent with an impaired Golgi-mediated glycosylation."

Independent clinical glycan profiling in the splice-variant families.

PMID:34022244 REFUTE DIRECT PRIMARY RESULT Human Clinical

"All results of second-line N-glycosylation analyses were initially normal."

Refutes a universal expectation of abnormal N-glycan screening; this mixed report included two COG4 siblings.

Abnormal O-glycan processing

Patient fibroblasts show altered O-glycan biosynthetic capacity on an artificial GAP acceptor, including increased Core1 structures and decreased extended Core2 glycans. Abnormal serum apoC-III O-glycoforms were detected in two adult siblings despite normal initial N-glycosylation screens.

protein O-linked glycosylation GO:0006493 ⚠ ABNORMAL

Experimental models

COG4-CDG patient fibroblasts PRIMARY CELL CULTURE

Show evidence (2 references)

PMID:21185756 SUPPORT DIRECT PRIMARY RESULT In Vitro

"HPLC analysis of purified, metabolically labeled, GAP molecules from patient fibroblasts revealed an increase in Galβ1,3GalNAc as well as Core1 monosialylated structures, with a decrease in extended Core2 based glycans."

Patient-cell assay of artificial-acceptor glycan products, rather than a direct census of native O-glycoproteins.

PMID:34022244 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"However, apoC-III 2-DE revealed characteristic "apoC-III1" pattern in P1 and specific "apoC-III0" patterns in P2 and P3."

P2 and P3 are the COG4 siblings; the ATP6V0A2 result in P1 is not attributed to COG4.

Altered Golgi ultrastructure

Patient fibroblasts can show disorganized Golgi stacks, with some normal stacks retained in the founding COG4 case. This morphology was not reproduced by p.Arg729Trp constructs in the tested engineered RPE1 and HEK293T backgrounds.

Golgi organization GO:0007030 ⚠ ABNORMAL

Experimental models

COG4-knockout RPE1 and HEK293T cells complemented with p.Arg729Trp CELL LINE

Show evidence (3 references)

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT In Vitro

"The overall Golgi integrity was substantially to very severely disrupted in all investigated cell lines"

TEM directly demonstrated disrupted Golgi integrity in the patient fibroblast panel, including COG4.

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Both the COG1- and COG4-deficient patient cells still show some stacks with a normal morphology, in contrast to the COG7 and COG8 patients."

Comparative TEM documents heterogeneous Golgi morphology and retained normal stacks in COG4 fibroblasts.

PMID:34603392 REFUTE DIRECT PRIMARY RESULT In Vitro

"The analysis revealed the Golgi stacks morphology and integrity were normal in all analyzed cell lines (Figure 4)."

Engineered point-mutant cells did not reproduce patient-fibroblast Golgi disruption.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

22

Blood 2

Abnormality of coagulation HP:0001928

Show evidence (1 reference)

PMID:42202558 SUPPORT REVIEW SYNTHESIS Human Clinical

"These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum..."

Coagulopathy is named directly.

Thrombocytopenia HP:0001873

Show evidence (1 reference)

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Blood tests revealed increased serum transaminases, alkaline phosphatases and LDH cholesterol levels, while the platelet counts were down."

Low platelet counts were reported in the founding patient.

Digestive 3

Abnormality of the liver HP:0001392

Coarse binding: source unspecified

Show evidence (1 reference)

PMID:42202558 SUPPORT REVIEW SYNTHESIS Human Clinical

"These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum..."

Liver involvement is named directly.

Cirrhosis HP:0001394

Show evidence (1 reference)

PMID:21185756 SUPPORT DIRECT BACKGROUND Human Clinical

"Briefly, the patient suffered from profound developmental delay, hypotonia, failure to thrive, seizures, coagulopathy, liver cirrhosis and recurrent infections that were eventually fatal."

Liver cirrhosis was reported in the second molecularly characterized COG4 patient.

Hepatic failure HP:0001399

Show evidence (1 reference)

PMID:34298581 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Patient P21 presented similar phenotypes, such as persistent jaundice, decreased liver function, abnormal coagulation, and status epilepticus. She also had disseminated intravascular coagulation and a history of recurrent bronchopneumonia and seizures. The patient finally died of liver and..."

Liver failure was a terminal complication in patient P21; this observation does not establish its frequency or isolate its cause from concurrent critical illness.

Head and Neck 2

Secondary microcephaly HP:0005484

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:42202558 SUPPORT REVIEW SYNTHESIS Human Clinical

"These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum..."

Names post-natal microcephaly, which is the secondary form.

Abnormal facial shape HP:0001999

Show evidence (1 reference)

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Some dysmorphic features were noted, like a peculiar face (down sloping frontal area and thick hair) combined with axial hyponia, slight peripheral hypertonia and hyperreflexia."

Case-specific facial dysmorphism; the quotation also contains the source spelling of axial hyponia.

Immune 1

Recurrent infections HP:0002719

Show evidence (1 reference)

PMID:42202558 SUPPORT REVIEW SYNTHESIS Human Clinical

"These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum..."

Recurrent infections are named directly.

Limbs 1

Limb hypertonia HP:0002509

Show evidence (1 reference)

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Some dysmorphic features were noted, like a peculiar face (down sloping frontal area and thick hair) combined with axial hyponia, slight peripheral hypertonia and hyperreflexia."

Case-level observation in the founding COG4 patient.

Metabolism 1

Elevated hepatic transaminase Elevated circulating hepatic transaminase concentration HP:0002910

Show evidence (1 reference)

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Blood tests revealed increased serum transaminases, alkaline phosphatases and LDH cholesterol levels, while the platelet counts were down."

Elevated transaminases were measured in the founding patient.

Musculoskeletal 2

Hypotonia HP:0001252

Show evidence (1 reference)

PMID:21185756 SUPPORT BACKGROUND Human Clinical

"Briefly, the patient suffered from profound developmental delay, hypotonia, failure to thrive, seizures, coagulopathy, liver cirrhosis and recurrent infections that were eventually fatal."

Case-level description naming hypotonia. No frequency is asserted because the support is a single patient rather than a series percentage.

Axial hypotonia HP:0008936

Show evidence (1 reference)

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Some dysmorphic features were noted, like a peculiar face (down sloping frontal area and thick hair) combined with axial hyponia, slight peripheral hypertonia and hyperreflexia."

Case-level observation in the founding COG4 patient. The source spells axial hypotonia as axial hyponia.

Nervous System 9

Global developmental delay HP:0001263

Show evidence (2 references)

PMID:42202558 SUPPORT REVIEW SYNTHESIS Human Clinical

"These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum..."

Severe global disability with a progressive course is the leading feature.

PMID:21185756 SUPPORT DIRECT BACKGROUND Human Clinical

"Briefly, the patient suffered from profound developmental delay, hypotonia, failure to thrive, seizures, coagulopathy, liver cirrhosis and recurrent infections that were eventually fatal."

Developmental delay is directly reported in this COG4 patient; no disease-wide frequency is inferred.

Brain atrophy HP:0012444

Course: PROGRESSIVE

Show evidence (1 reference)

PMID:42202558 SUPPORT REVIEW SYNTHESIS Human Clinical

"These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum..."

Brain atrophy is named directly.

Seizure HP:0001250

Show evidence (2 references)

PMID:42202558 SUPPORT REVIEW SYNTHESIS Human Clinical

"These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum..."

Seizures are named directly.

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Until the fourth month the boy had a normal development, but after a vaccination the child started fever and progressive irritability. He was hospitalized due to complex seizures, which were eventually suppressed by phenobarbital."

Documents the founding patient's onset sequence and seizures, without establishing a causal trigger.

Absent speech HP:0001344

Show evidence (1 reference)

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"At the age of 3 years the child presented with microcephaly, bilateral cerebral atrophy of the frontotemporal regions, a mild degree of ataxia, brisk, uncoordinated movements, absence of speech and moderate psychomotor delay."

Direct observation of absent speech in the COG4 patient, rather than a pooled all-COG ranking.

Hyperreflexia HP:0001347

Show evidence (1 reference)

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Some dysmorphic features were noted, like a peculiar face (down sloping frontal area and thick hair) combined with axial hyponia, slight peripheral hypertonia and hyperreflexia."

Hyperreflexia was documented in the founding patient.

Ataxia HP:0001251

Show evidence (1 reference)

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"At the age of 3 years the child presented with microcephaly, bilateral cerebral atrophy of the frontotemporal regions, a mild degree of ataxia, brisk, uncoordinated movements, absence of speech and moderate psychomotor delay."

Mild ataxia was observed at age three in the founding patient.

Status epilepticus HP:0002133

Show evidence (1 reference)

PMID:34298581 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Patient P21 presented similar phenotypes, such as persistent jaundice, decreased liver function, abnormal coagulation, and status epilepticus. She also had disseminated intravascular coagulation and a history of recurrent bronchopneumonia and seizures. The patient finally died of liver and..."

Status epilepticus was reported in patient P21 in the pediatric intensive care cohort.

Frontotemporal cerebral atrophy HP:0006892

Show evidence (1 reference)

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"At the age of 3 years the child presented with microcephaly, bilateral cerebral atrophy of the frontotemporal regions, a mild degree of ataxia, brisk, uncoordinated movements, absence of speech and moderate psychomotor delay."

Case-level observation in the founding COG4 patient.

Cognitive impairment HP:0100543

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/ SUPPORT DIRECT REVIEW SYNTHESIS Human Clinical

"Features include severe cognitive impairment, seizures, hypotonia, liver cirrhosis, recurrent infections and early death. Less common features may include microcephaly, ataxia, and brisk uncoordinated movements"

The COG4-specific paragraph of the retired overview supports cognitive impairment, without supplying a reliable frequency estimate. Later primary reports include survival to adulthood.

Growth 1

Failure to thrive HP:0001508

Show evidence (1 reference)

PMID:21185756 SUPPORT BACKGROUND Human Clinical

"Briefly, the patient suffered from profound developmental delay, hypotonia, failure to thrive, seizures, coagulopathy, liver cirrhosis and recurrent infections that were eventually fatal."

Case-level description naming failure to thrive. No frequency is asserted for the same reason as hypotonia.

🧬

Genetic Associations

1

COG4

Gene: COG4 hgnc:18620 relationship_type: CAUSATIVE variant_origin: GERMLINE

Show evidence (5 references)

PMID:19494034 SUPPORT Human Clinical

"We report a new CDG-II patient harbouring a p.R729W missense mutation in COG4 combined with a submicroscopical deletion."

The founding report identifying COG4 as the cause of this CDG subtype, and the genotype that established it.

PMID:21185756 SUPPORT Human Clinical

"Here we present data identifying a previously reported CDG-IIx case from Singapore as a new COG4 patient with 2 novel mutations leading to p.E233X and p.L773R; with p.E233X being a de novo mutation."

Adds a second independent genotype to the recessive allelic spectrum.

PMID:42202558 SUPPORT Human Clinical

"Whole transcriptome sequencing and reverse transcriptase PCR from peripheral blood detected an aberrant COG4 transcript which features skipping of exon 12 and results in a frameshift, predicted to introduce a premature termination codon."

Establishes the molecular consequence of the founder splice allele at the transcript level rather than by prediction alone.

+ 2 more references

🔬

Variants

1

COG4 c.1647+5G>A

Gene: COG4 hgnc:18620 single nucleotide variant

Genomic context: intron

Homozygous splice-altering variant identified in four affected individuals from two Italian families. Blood transcriptome sequencing and RT-PCR demonstrated exon 12 skipping. The resulting frameshift predicts a premature termination codon; protein abundance and nonsense-mediated decay were not established by the quoted RNA result.

Show evidence (1 reference)

PMID:42202558 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Whole transcriptome sequencing and reverse transcriptase PCR from peripheral blood detected an aberrant COG4 transcript which features skipping of exon 12 and results in a frameshift, predicted to introduce a premature termination codon."

Separates the measured blood RNA splice defect from the predicted coding consequence.

🗃️

External Assertions

2

OMIM COG4-CDG record

OMIM disease record OMIM:613489

OMIM phenotype entry for congenital disorder of glycosylation type IIj, the autosomal recessive COG4-related disorder this entry describes. Distinct from OMIM:618150, Saul-Wilson syndrome, which is the dominant COG4 allele.

Orphanet COG4-CDG record

Orphanet disease record ORPHA:263487

Orphanet record for COG4-CDG.

💊

Medical Actions

5

Phenobarbital for seizures

Action: Anticonvulsant Therapy NCIT:C64172

Agent: phenobarbital CHEBI:8069

Platform: Small molecule

Phenobarbital suppressed complex seizures in the founding patient. This is a single-patient symptomatic response; no comparative efficacy or disease-modifying effect is established.

Target Phenotypes: Seizure HP:0001250

Show evidence (1 reference)

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"He was hospitalized due to complex seizures, which were eventually suppressed by phenobarbital."

Direct clinical treatment response in one patient.

Nutritional and developmental support

Category: Therapeutic Action: Supportive Care NCIT:C15747

The retired GeneReviews overview recommends nutritional support for failure to thrive and occupational, physical and speech therapy for developmental delay across N-linked and multiple-pathway CDGs. These are general supportive-care recommendations applicable to the corresponding COG4 manifestations, rather than COG4 intervention-trial results.

Target Phenotypes: Failure to thrive HP:0001508 Global developmental delay HP:0001263

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/ SUPPORT INDIRECT REVIEW SYNTHESIS Other

"Some children require placement of a nasogastric tube or gastrostomy tube for nutritional support until oral motor skills improve."

Historical group-level nutritional support; does not establish COG4-specific tube-feeding outcomes.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/ SUPPORT INDIRECT REVIEW SYNTHESIS Other

"Occupational therapy, physical therapy, and speech therapy should be instituted. As the developmental gap widens between children with CDG and their unaffected peers, parents, educators, and therapists need continued counseling and support."

General developmental-care recommendation in the retired overview, not a COG4-specific efficacy study.

Hepatic and coagulation surveillance

Category: Monitoring Action: Clinical Evaluation NCIT:C124351

The retired group-level overview includes liver-function and coagulation-factor surveillance, with hematology assessment before surgery. This is general CDG guidance for manifestations documented in COG4-CDG; the surveillance interval has not been validated specifically in COG4 patients.

Show evidence (2 references)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/ SUPPORT INDIRECT REVIEW SYNTHESIS Other

"Consultation with a hematologist is recommended to document the pro- and anti- clotting factor levels and coagulation status."

General coagulation assessment recommendation from the retired CDG overview.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/ SUPPORT INDIRECT REVIEW SYNTHESIS Other

"Liver function tests; thyroid panel; serum concentrations of the clotting factors protein C, protein S, factor IX, and antithrombin III"

The source lists these under annual surveillance for the broad CDG group; only hepatic/coagulation monitoring is modeled here.

Genetic counseling and reproductive planning

Category: Counseling / Informational Action: Genetic Counseling NCIT:C15240

Counseling includes segregation and carrier assessment, conditional recurrence risk and reproductive options. The historical overview states that prenatal and preimplantation testing become possible after identification of familial pathogenic variants. A de novo allele in one COG4 family means parental carrier status must be established rather than assumed.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/ SUPPORT INDIRECT REVIEW SYNTHESIS Other

"Once the ... pathogenic variant ... (s) have been identified in the family, ... prenatal testing ... for a pregnancy at increased risk and ... preimplantation genetic testing ... for a ... congenital ... disorder of N-linked glycosylation or multiple pathway are possible."

General molecularly defined CDG counseling, applicable once familial COG4 variants are established.

Medication precautions with hepatic involvement

Category: Counseling / Informational Action: Counseling NCIT:C61547

The retired overview advises caution with acetaminophen and other hepatically metabolized agents. This is historical general CDG guidance, not evidence that all such agents are contraindicated in COG4-CDG; medication decisions require individual hepatic assessment.

Show evidence (1 reference)

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/ SUPPORT INDIRECT REVIEW SYNTHESIS Other

"Acetominophen and other agents metabolized by the liver should be used with caution."

Historical general medication precaution; the source spells acetaminophen as acetominophen. It does not report a COG4-specific adverse-drug study.

🔬

Diagnosis

5

Serum N-glycan mass spectrometry

Serum N-glycan mass spectrometry can reveal deficient galactosylation and sialylation, as in the 2026 families. A normal result does not exclude COG4-CDG: both transferrin and broader second-line N-glycosylation analyses were initially normal in two adult siblings.

Show evidence (2 references)

PMID:42202558 SUPPORT Human Clinical

"Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling of serum N-glycans showed mildly deficient galactosylation and sialylation, consistent with an impaired Golgi-mediated glycosylation."

The glycan assay and the abnormality it detects in this disorder.

PMID:34022244 REFUTE DIRECT PRIMARY RESULT Human Clinical

"All results of second-line N-glycosylation analyses were initially normal."

Limits diagnostic sensitivity; an abnormal apoC-III O-glycan pattern provided additional evidence in the COG4 siblings.

Serum IgG N-glycosylation analysis

Serum IgG N-glycan abnormalities analogous to total serum findings were reported in the 2026 families. Diagnostic sensitivity, specificity and comparative accessibility were not established by that observation.

Show evidence (1 reference)

PMID:42202558 SUPPORT Human Clinical

"As a novel finding, N-glycosylation study of serum IgG showed analogous N-glycan anomalies."

Documents the IgG glycan finding as newly reported in this disorder.

Serum transferrin isoelectric focusing

Transferrin isoelectric focusing can show an abnormal type 2 pattern, as in the founding COG4 patient. Screening can also be normal in affected individuals and therefore cannot by itself exclude the disorder.

Show evidence (2 references)

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Because CDG was suspected, isoelectric focusing of serum transferrin was performed and showed a type 2 pattern"

Documents an abnormal transferrin screen in the founding COG4-CDG patient.

PMID:34022244 REFUTE Human Clinical

"We identified three cases of congenital disorders of glycosylation (CDG) with Golgi homeostasis disruption, one ATP6V0A2-CDG and two COG4-CDG, with normal transferrin screening analyses."

Graded REFUTE against the implicit claim that transferrin screening detects this disorder: the cited cases are COG4-CDG patients in whom it did not.

Apolipoprotein C-III two-dimensional electrophoresis

Two-dimensional electrophoresis of mucin core 1 O-glycosylated apoC-III detected abnormal apoC-III0 patterns in two COG4 siblings whose initial N-glycosylation analyses were normal. The result helped reclassify their homozygous COG4 variant as likely pathogenic; performance across all COG4 genotypes remains uncertain.

Show evidence (2 references)

PMID:34022244 SUPPORT Human Clinical

"However, apoC-III 2-DE revealed characteristic "apoC-III1" pattern in P1 and specific "apoC-III0" patterns in P2 and P3."

Reports what the assay showed in the patients, including the two COG4-CDG cases, which is the claim this entry makes.

PMID:34022244 SUPPORT Human Clinical

"Furthermore, they show the potential of apoC-III 2-DE in diagnosing this type of CDG, with highly specific patterns in COG-CDG."

States the diagnostic value of the assay in COG-CDG specifically.

COG4 molecular and RNA analysis

Identify biallelic COG4 variants through sequencing with deletion analysis where indicated, and assess segregation. RNA studies can resolve splice consequences. Biochemical evidence can support interpretation of uncertain variants even with normal transferrin screening.

Show evidence (4 references)

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"We report a new CDG-II patient harbouring a p.R729W missense mutation in COG4 combined with a submicroscopical deletion."

A deletion in trans to a sequence variant shows why a negative second sequence allele does not exhaust molecular testing.

PMID:42202558 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"Whole transcriptome sequencing and reverse transcriptase PCR from peripheral blood detected an aberrant COG4 transcript which features skipping of exon 12 and results in a frameshift, predicted to introduce a premature termination codon."

RNA studies demonstrated aberrant splicing after exome identification of the intronic variant.

PMID:34022244 SUPPORT DIRECT PRIMARY RESULT Human Clinical

"In P2 and P3, this allowed reclassifying the variant as likely pathogenic according to ACMG guidelines."

In context, abnormal apoC-III patterns supported interpretation of the homozygous COG4 variant.

+ 1 more reference

📊

Prevalence

1

Worldwide, cases reported in the literature

Cases In Literature Ultra Rare

The 2026 report describes six previously reported individuals and adds four affected people from two Italian families sharing a founder haplotype. This is a source-specific literature count, not a population prevalence estimate; case ascertainment and counting differ between publications.

Show evidence (1 reference)

PMID:42202558 SUPPORT Human Clinical

"COG4-CDG(ar) has been described in six individuals to date, and its clinical manifestations and disease mechanisms remain poorly understood."

Gives the reported case count prior to that paper's own additions.

🔀

Differential Diagnoses

2

Conditions with similar clinical presentations that must be differentiated from COG4-Congenital Disorder of Glycosylation:

Saul-Wilson syndrome (COG4, dominant)

Overlapping Features Saul-Wilson syndrome is a skeletal dysplasia with primordial dwarfism caused by recurrent heterozygous de novo p.Gly516Arg. Patient fibroblasts showed preserved COG4 abundance and accelerated retrograde recycling, contrasting with the reduced abundance and delayed recycling documented in recessive COG4-CDG fibroblasts.

Show evidence (2 references)

PMID:30290151 SUPPORT Human Clinical

"All affected subjects harbored heterozygous de novo variants in COG4, giving rise to the same recurrent amino acid substitution (p.Gly516Arg)."

Establishes the dominant, single-recurrent-allele genetics that separate Saul-Wilson from recessive COG4-CDG.

PMID:30290151 SUPPORT In Vitro

"Affected individuals' fibroblasts, whose COG4 mRNA and protein were not decreased, exhibited delayed anterograde vesicular trafficking from the ER to the Golgi and accelerated retrograde vesicular recycling from the Golgi to the ER."

The mechanistic contrast that carries the lump/split argument: normal COG4 levels and accelerated rather than delayed retrograde transport.

Lobe B COG-CDG (COG5-8)

Overlapping Features Other COG-subunit disorders share trafficking and glycosylation abnormalities and require gene-specific molecular diagnosis. A historical lobe A versus lobe B severity hypothesis compared mutation classes and residual expression; it does not establish that every lobe B disorder is milder or provide individual COG4 prognosis.

Show evidence (1 reference)

PMID:28848061 SUPPORT REVIEW SYNTHESIS Human Clinical

"Second, nearly all of the 27 patients with lobe B COG-CDG had bi-allelic truncating mutations, as compared with only one of the six patients with lobe A COG-CDG."

Historical comparison of mutation classes across COG disorders, not a validated individual severity prediction.

🧫

Experimental Models

2

COG4-CDG patient fibroblasts PRIMARY_CELL_CULTURE

Primary fibroblasts from the founding compound-heterozygous patients model COG4 protein abundance, BFA-induced retrograde trafficking and glycan biosynthesis. Wild-type COG4 viral complementation did not restore a normal BFA response in the tested patient cells. Increasing COG4 expression also impaired the BFA response in control fibroblasts in the founding study.

Pathograph links

Delayed Golgi retrograde transport recapitulates fidelity: moderate observes: cellular

Limitations: BFA redistributes Golgi proteins pharmacologically; the assay does not isolate every physiological tethering or fusion step, and fibroblasts do not establish organ-specific mechanisms.

Divergences from the human mechanism

boundary omission qualifying

Cultured cells lack the neuronal, hepatic and systemic context required to explain the clinical disorder.

Show evidence (1 reference)

PMID:21185756 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Importantly, patient fibroblasts exhibited a delay in Brefeldin A (BFA) induced retrograde transport, a common characteristic seen in COG deficiencies."

Direct patient-cell transport readout.

Abnormal O-glycan processing partially recapitulates fidelity: moderate observes: cellular

Limitations: GAP is an artificial acceptor of glycan biosynthesis; products mimic glycan chains but do not enumerate native glycoprotein substrates.

Show evidence (1 reference)

PMID:21185756 SUPPORT DIRECT PRIMARY RESULT In Vitro

"HPLC analysis of purified, metabolically labeled, GAP molecules from patient fibroblasts revealed an increase in Galβ1,3GalNAc as well as Core1 monosialylated structures, with a decrease in extended Core2 based glycans."

Patient-derived biosynthetic-capacity readout.

Show evidence (2 references)

PMID:21185756 SUPPORT DIRECT PRIMARY RESULT In Vitro

"To our surprise transduction of patient fibroblasts with the wild-type COG4 did not restore the normal BFA response even using various viral titers or infection times."

Failed complementation is an experimental limitation, not evidence of an effective gene therapy.

PMID:19494034 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Surprisingly, stable transduction of control cells with COG4 (thereby doubling expression levels) resulted in a retrograde trafficking defect, reminiscent of that observed in patient cells."

Increasing COG4 expression impaired the control-cell trafficking assay, limiting a simple dosage-rescue interpretation.

COG4-knockout RPE1 and HEK293T cells complemented with p.Arg729Trp CELL_LINE

CRISPR COG4 knockouts were complemented by lentiviral myc-tagged wild-type or mutant COG4 under a cloned COG4 promoter. The p.Arg729Trp constructs restored many knockout abnormalities while retaining an N-glycosylation defect. These are complemented knockout backgrounds, not endogenous-locus patient-genotype knock-ins.

Pathograph links

Abnormal N-glycan processing partially recapitulates fidelity: moderate observes: cellular p.Arg729Trp cells show increased GNL binding consistent with abnormal N-glycosylation.

Limitations: Tagged constructs in engineered non-patient backgrounds; lectin binding is a glycan-class readout and does not reproduce every serum glycan or clinical phenotype.

Divergences from the human mechanism

boundary omission qualifying

Cultured cells lack the neuronal, hepatic and systemic context required to explain the clinical disorder.

Show evidence (1 reference)

PMID:34603392 SUPPORT DIRECT PRIMARY RESULT In Vitro

"In contrast, binding of GNL to plasma membrane of non-permeabilized cells was increased in both mutant cell lines, but most significantly in cells expressing COG4-R729W (Figures 6A,B, Supplementary Figure S3B)."

Direct lectin readout in engineered p.Arg729Trp cells.

Altered Golgi ultrastructure fails to recapitulate observes: cellular

Limitations: Normal Golgi stack morphology in these engineered point-mutant cells contrasts with patient-fibroblast disruption.

Show evidence (1 reference)

PMID:34603392 REFUTE DIRECT PRIMARY RESULT In Vitro

"The analysis revealed the Golgi stacks morphology and integrity were normal in all analyzed cell lines (Figure 4)."

Negative morphology result prevents treating this model as reproducing all patient-cell defects.

Findings

p.Arg729Trp restored B4GalT1 abundance and Lamp2/TMEM165 glycosylation in the tested knockout backgrounds.

Show evidence (1 reference)

PMID:34603392 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Expression of wild-type and mutant COG4 rescued stability and glycosylation of all three tested proteins (Figure 2A, Supplementary Figure S1A)."

The proteins are B4GalT1, Lamp2 and TMEM165 in the preceding experimental description.

GS15 localization and abundance were not significantly altered in the rescued point-mutant lines.

Show evidence (1 reference)

PMID:34603392 SUPPORT DIRECT PRIMARY RESULT In Vitro

"This result indicates the investigated COG4 mutations do not significantly affect GS15 localization or stability."

A measured negative result for the tested point-mutant cell lines.

Heparan sulfate proteoglycan core-protein accumulation was increased in p.Arg729Trp and p.Gly516Arg lines; this alone did not explain the distinct Saul-Wilson phenotype.

Show evidence (1 reference)

PMID:34603392 SUPPORT DIRECT PRIMARY RESULT In Vitro

"WB revealed a significant increase in core proteins of HSPGs accumulation on the cell surface of both COG4-G516R and COG4-R729W mutant cell lines."

Shared HSPG phenotype does not establish a unique clinical mechanism.

Show evidence (4 references)

PMID:34603392 SUPPORT In Vitro

"Using a combination of CRISPR/Cas9 and lentiviral transduction technologies, both myc-tagged wild-type and mutant (G516R and R729W) COG4 proteins were expressed under the endogenous COG4 promoter."

Documents knockout plus lentiviral complementation with promoter-controlled constructs; it does not by itself exclude expression-system artifacts.

PMID:34603392 SUPPORT DIRECT PRIMARY RESULT In Vitro

"Expression of wild-type and mutant COG4 rescued stability and glycosylation of all three tested proteins (Figure 2A, Supplementary Figure S1A)."

The proteins are B4GalT1, Lamp2 and TMEM165 in the preceding experimental description.

PMID:34603392 SUPPORT DIRECT PRIMARY RESULT In Vitro

"This result indicates the investigated COG4 mutations do not significantly affect GS15 localization or stability."

A measured negative result for the tested point-mutant cell lines.

+ 1 more reference

🐁

Animal Models

1

cog4 b1312 homozygous null Danio rerio

The b1312 allele is a 13-base-pair exon 12 deletion with a frameshift and premature stop. Null larvae showed delayed epithelial projection growth and reduced extracellular-matrix secretion during semicircular-canal development. This gene-loss model probes Cog4 function; its ear phenotype does not establish hearing impairment in recessive human COG4-CDG.

Species

Danio rerio

Genotype

cog4 b1312 homozygous null

Pathograph links

Biallelic COG4 dysfunction perturbs observes: organism

Limitations: Complete zebrafish gene loss differs from residual-function human alleles. The study examines ear morphogenesis and does not reproduce or quantify the human multisystem phenotype.

Divergences from the human mechanism

boundary omission qualifying

Larval inner-ear developmental readouts do not establish the neurological and hepatic course of human COG4-CDG.

Show evidence (1 reference)

PMID:30287385 SUPPORT DIRECT BACKGROUND Model Organism

"The cog4b1312 allele is a 13 bp deletion in exon 12 of cog4. The mutation introduces a frameshift followed by an early stop codon (Ferreira et al., in press)."

Defines the gene-loss perturbation used in the developmental study.

Show evidence (1 reference)

PMID:30287385 SUPPORT DIRECT PRIMARY RESULT Model Organism

"Here, we show that formation of the pillars is delayed and that secretion of extracellular matrix components (ECM) is impaired in cog4-/- mutants."

Direct developmental observations in null zebrafish.

{ }

Source YAML

click to show

name: COG4-Congenital Disorder of Glycosylation
creation_date: '2026-09-06T15:45:00Z'
category: Mendelian
description: >-
  COG4-CDG (CDG-IIj) is an autosomal recessive congenital disorder of glycosylation caused by biallelic
  deleterious COG4 variants. COG4 is a lobe A subunit of the conserved oligomeric Golgi complex involved
  in retrograde vesicle trafficking. Patient fibroblasts can show reduced COG4 abundance, delayed retrograde
  transport and altered Golgi morphology. Abnormal N- and O-glycan processing is reported, although transferrin
  and broader N-glycan screens can be normal in affected individuals. The clinical spectrum includes developmental
  impairment, postnatal microcephaly, brain atrophy, seizures, hypotonia, coagulopathy, liver disease
  and recurrent infections. A progressive course and severe disability are described, with survival ranging
  from early childhood deaths to adulthood. The recessive disorder is distinct from dominant COG4-related
  Saul-Wilson syndrome caused by p.Gly516Arg.
synonyms:
- COG4-CDG
- CDG-IIj
- CDG IIj
- congenital disorder of glycosylation, type IIj
- carbohydrate deficient glycoprotein syndrome type IIj
- COG4-CDG(ar)
- autosomal recessive COG4-related congenital disorder of glycosylation
disease_term:
  preferred_term: COG4-congenital disorder of glycosylation
  term:
    id: MONDO:0013281
    label: COG4-congenital disorder of glycosylation
parents:
- Congenital Disorder of Glycosylation
references:
- reference: PMID:42202558
  title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
- reference: PMID:31804708
  title: 'Hypothesis: determining phenotypic specificity facilitates understanding of pathophysiology in rare genetic disorders.'
- reference: PMID:19494034
  title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
- reference: PMID:21185756
  title: Identification of the first COG-CDG patient of Indian origin.
- reference: PMID:34022244
  title: 'Normal transferrin patterns in congenital disorders of glycosylation with Golgi homeostasis disruption: apolipoprotein C-III at the rescue!'
- reference: PMID:34603392
  title: Development and Initial Characterization of Cellular Models for COG Complex-Related CDG-II Diseases.
- reference: PMID:19651599
  title: Structural basis for a human glycosylation disorder caused by mutation of the COG4 gene.
- reference: PMID:34298581
  title: Expanding the genotypes and phenotypes for 19 rare diseases by exome sequencing performed in pediatric intensive care unit.
- reference: PMID:30287385
  title: Cog4 is required for protrusion and extension of the epithelium in the developing semicircular canals.
- reference: PMID:30290151
  title: A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation.
- reference: PMID:28848061
  title: 'Hypothesis: lobe A (COG1-4)-CDG causes a more severe phenotype than lobe B (COG5-8)-CDG.'
- reference: PMID:20301507
  title: Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.
  tags:
  - GeneReviews
- reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/
  title: Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY - GeneReviews® - NCBI Bookshelf
external_assertions:
- name: OMIM COG4-CDG record
  source: OMIM
  assertion_type: disease_record
  external_id: OMIM:613489
  description: OMIM phenotype entry for congenital disorder of glycosylation type IIj, the autosomal recessive COG4-related disorder this entry describes. Distinct from OMIM:618150, Saul-Wilson syndrome, which is the dominant COG4 allele.
- name: Orphanet COG4-CDG record
  source: Orphanet
  assertion_type: disease_record
  external_id: ORPHA:263487
  description: Orphanet record for COG4-CDG.
inheritance:
- name: Autosomal Recessive
  description: >-
    Biallelic COG4 variants cause the recessive disorder. Reported configurations include missense/deletion,
    nonsense/missense and homozygous splice-altering genotypes. A de novo allele can occur as one member
    of a recessive compound-heterozygous genotype; this differs from the dominant p.Gly516Arg mechanism
    of Saul-Wilson syndrome. When both parents carry a pathogenic recessive allele, standard Mendelian
    counseling gives each pregnancy a 25% affected, 50% carrier and 25% unaffected noncarrier probability.
    This assumes confirmed parental carrier status; the reported de novo compound-heterozygous configuration
    requires family-specific assessment.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Exome sequencing identified the homozygous COG4 c.1647+5G>A variant in four affected individuals from two apparently unrelated Italian families.
    explanation: Documents homozygous inheritance of a single COG4 allele in four affected individuals across two families, establishing the recessive mode.
  - reference: PMID:34298581
    reference_title: Expanding the genotypes and phenotypes for 19 rare diseases by exome sequencing performed in pediatric intensive care unit.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      The first variant was inherited from her father, and the second was inherited from her mother.
    explanation: >-
      The preceding case description identifies COG4 p.Glu419Ter and p.Cys314Tyr in patient P21, with
      segregation establishing opposite parental origins.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/
    reference_title: Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
    snippet: >-
      At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance
      of being an asymptomatic ... carrier ... and a 25% chance of being unaffected and not a carrier.
    explanation: >-
      General autosomal-recessive counseling from the retired overview, applicable to COG4 families when
      both parents are carriers; not an unconditional recurrence estimate for a de novo allele.
prevalence:
- population: Worldwide, cases reported in the literature
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    The 2026 report describes six previously reported individuals and adds four affected people from two
    Italian families sharing a founder haplotype. This is a source-specific literature count, not a population
    prevalence estimate; case ascertainment and counting differ between publications.
  evidence:
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: COG4-CDG(ar) has been described in six individuals to date, and its clinical manifestations and disease mechanisms remain poorly understood.
    explanation: Gives the reported case count prior to that paper's own additions.
genetic:
- name: COG4
  notes: >-
    Reported recessive genotypes include p.Arg729Trp with a deletion in trans, p.Glu233Ter with p.Leu773Arg,
    p.Glu419Ter with p.Cys314Tyr, and homozygous c.1647+5G>A. The latter causes exon 12 skipping in blood
    RNA, with a frameshift predicted to introduce a premature stop; this assay does not establish complete
    loss of protein in every tissue. The p.Arg729Trp substitution affects a structurally important C-terminal
    region. Dominant p.Gly516Arg causes the separate Saul-Wilson syndrome.
  gene_term:
    preferred_term: COG4
    term:
      id: hgnc:18620
      label: COG4
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: We report a new CDG-II patient harbouring a p.R729W missense mutation in COG4 combined with a submicroscopical deletion.
    explanation: The founding report identifying COG4 as the cause of this CDG subtype, and the genotype that established it.
  - reference: PMID:21185756
    reference_title: Identification of the first COG-CDG patient of Indian origin.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Here we present data identifying a previously reported CDG-IIx case from Singapore as a new COG4 patient with 2 novel mutations leading to p.E233X and p.L773R; with p.E233X being a de novo mutation.
    explanation: Adds a second independent genotype to the recessive allelic spectrum.
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Whole transcriptome sequencing and reverse transcriptase PCR from peripheral blood detected an aberrant COG4 transcript which features skipping of exon 12 and results in a frameshift, predicted to introduce a premature termination codon.
    explanation: Establishes the molecular consequence of the founder splice allele at the transcript level rather than by prediction alone.
  - reference: PMID:34298581
    reference_title: Expanding the genotypes and phenotypes for 19 rare diseases by exome sequencing performed in pediatric intensive care unit.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      For example, patient P21 was found compound heterozygous variants c.1255G>T (p.Glu419Ter) and c.941G>A
      (p.Cys314Tyr) in COG4.
    explanation: >-
      Adds a segregated nonsense/missense genotype in a child with severe multisystem disease.
  - reference: PMID:19651599
    reference_title: Structural basis for a human glycosylation disorder caused by mutation of the COG4 gene.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Arg 729 is found to occupy a key position at the center of a salt bridge network, thereby stabilizing
      Cog4's small C-terminal domain.
    explanation: >-
      Crystallographic evidence locates the residue altered by p.Arg729Trp; structural inference does
      not establish clinical severity.
pathophysiology:
- name: Biallelic COG4 dysfunction
  biological_scale: MOLECULAR
  gene:
    preferred_term: COG4
    term:
      id: hgnc:18620
      label: COG4
  description: >-
    Biallelic deleterious COG4 variants impair the function of this Golgi tethering-complex subunit. Alleles
    can reduce protein abundance or alter function while retaining complex assembly; the homozygous splice
    allele produces an aberrant transcript.
  evidence:
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: >-
      is caused by biallelic deleterious variants in COG4, which encodes a component of the conserved
      oligomeric Golgi complex lobe A.
    explanation: >-
      Establishes the causal gene and recessive disease context.
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Whole transcriptome sequencing and reverse transcriptase PCR from peripheral blood detected an aberrant
      COG4 transcript which features skipping of exon 12 and results in a frameshift, predicted to introduce
      a premature termination codon.
    explanation: >-
      Direct RNA evidence for one disease-associated genotype.
  downstream:
  - target: Reduced COG4 Expression
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19494034
      reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: The resulting downregulation of COG4 expression additionally affects expression or stability of other lobe A subunits.
      explanation: >-
        Reduced COG4 and additional lobe A subunit effects were observed in the founding patient fibroblasts.
    - reference: PMID:21185756
      reference_title: Identification of the first COG-CDG patient of Indian origin.
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: As a result, COG4 protein expression was dramatically reduced, while expression of the other subunits remained unaffected.
      explanation: >-
        A different patient genotype showed isolated COG4 reduction; the studies need not represent a
        biological contradiction.
  - target: Altered Golgi ultrastructure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19494034
      reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: >-
        The overall Golgi integrity was substantially to very severely disrupted in all investigated cell lines
      explanation: >-
        TEM showed disrupted Golgi integrity in the patient fibroblast panel, including the COG4 line;
        the intervening molecular steps are not established by this observation.
  - target: Global developmental delay
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42202558
      reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum proteins.
      explanation: >-
        Clinical association of global developmental delay with COG4-CDG. The intervening molecular and
        tissue mechanisms are unresolved; the edge does not assert a measured direct causal step.
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Secondary microcephaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42202558
      reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum proteins.
      explanation: >-
        Clinical association of secondary microcephaly with COG4-CDG. The intervening molecular and tissue
        mechanisms are unresolved; the edge does not assert a measured direct causal step.
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Brain atrophy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42202558
      reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum proteins.
      explanation: >-
        Clinical association of brain atrophy with COG4-CDG. The intervening molecular and tissue mechanisms
        are unresolved; the edge does not assert a measured direct causal step.
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Seizure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42202558
      reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum proteins.
      explanation: >-
        Clinical association of seizure with COG4-CDG. The intervening molecular and tissue mechanisms
        are unresolved; the edge does not assert a measured direct causal step.
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Abnormality of coagulation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42202558
      reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum proteins.
      explanation: >-
        Clinical association of abnormality of coagulation with COG4-CDG. The intervening molecular and
        tissue mechanisms are unresolved; the edge does not assert a measured direct causal step.
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Abnormality of the liver
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42202558
      reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum proteins.
      explanation: >-
        Clinical association of abnormality of the liver with COG4-CDG. The intervening molecular and
        tissue mechanisms are unresolved; the edge does not assert a measured direct causal step.
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Recurrent infections
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:42202558
      reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum proteins.
      explanation: >-
        Clinical association of recurrent infections with COG4-CDG. The intervening molecular and tissue
        mechanisms are unresolved; the edge does not assert a measured direct causal step.
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Abnormal facial shape
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19494034
      reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        Some dysmorphic features were noted, like a peculiar face (down sloping frontal area and thick
        hair) combined with axial hyponia, slight peripheral hypertonia and hyperreflexia.
      explanation: >-
        Clinical association of abnormal facial shape with COG4-CDG. The intervening molecular and tissue
        mechanisms are unresolved; the edge does not assert a measured direct causal step.
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Absent speech
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19494034
      reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        At the age of 3 years the child presented with microcephaly, bilateral cerebral atrophy of the
        frontotemporal regions, a mild degree of ataxia, brisk, uncoordinated movements, absence of speech
        and moderate psychomotor delay.
      explanation: >-
        Clinical association of absent speech with COG4-CDG. The intervening molecular and tissue mechanisms
        are unresolved; the edge does not assert a measured direct causal step.
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Hypotonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21185756
      reference_title: Identification of the first COG-CDG patient of Indian origin.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Briefly, the patient suffered from profound developmental delay, hypotonia, failure to thrive, seizures, coagulopathy, liver cirrhosis and recurrent infections that were eventually fatal.
      explanation: >-
        Clinical association of hypotonia with COG4-CDG. The intervening molecular and tissue mechanisms
        are unresolved; the edge does not assert a measured direct causal step.
      quote_role: BACKGROUND
      directness: INDIRECT
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Failure to thrive
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21185756
      reference_title: Identification of the first COG-CDG patient of Indian origin.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: Briefly, the patient suffered from profound developmental delay, hypotonia, failure to thrive, seizures, coagulopathy, liver cirrhosis and recurrent infections that were eventually fatal.
      explanation: >-
        Clinical association of failure to thrive with COG4-CDG. The intervening molecular and tissue
        mechanisms are unresolved; the edge does not assert a measured direct causal step.
      quote_role: BACKGROUND
      directness: INDIRECT
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Cirrhosis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21185756
      reference_title: Identification of the first COG-CDG patient of Indian origin.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: BACKGROUND
      directness: INDIRECT
      snippet: >-
        Briefly, the patient suffered from profound developmental delay, hypotonia, failure to thrive,
        seizures, coagulopathy, liver cirrhosis and recurrent infections that were eventually fatal.
      explanation: >-
        Clinical association of cirrhosis with COG4-CDG. The intervening molecular and tissue mechanisms
        are unresolved; the edge does not assert a measured direct causal step.
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Elevated hepatic transaminase
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19494034
      reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        Blood tests revealed increased serum transaminases, alkaline phosphatases and LDH cholesterol
        levels, while the platelet counts were down.
      explanation: >-
        Clinical association of elevated hepatic transaminase with COG4-CDG. The intervening molecular
        and tissue mechanisms are unresolved; the edge does not assert a measured direct causal step.
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Thrombocytopenia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19494034
      reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        Blood tests revealed increased serum transaminases, alkaline phosphatases and LDH cholesterol
        levels, while the platelet counts were down.
      explanation: >-
        Clinical association of thrombocytopenia with COG4-CDG. The intervening molecular and tissue mechanisms
        are unresolved; the edge does not assert a measured direct causal step.
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Hyperreflexia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19494034
      reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        Some dysmorphic features were noted, like a peculiar face (down sloping frontal area and thick
        hair) combined with axial hyponia, slight peripheral hypertonia and hyperreflexia.
      explanation: >-
        Clinical association of hyperreflexia with COG4-CDG. The intervening molecular and tissue mechanisms
        are unresolved; the edge does not assert a measured direct causal step.
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Ataxia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19494034
      reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        At the age of 3 years the child presented with microcephaly, bilateral cerebral atrophy of the
        frontotemporal regions, a mild degree of ataxia, brisk, uncoordinated movements, absence of speech
        and moderate psychomotor delay.
      explanation: >-
        Clinical association of ataxia with COG4-CDG. The intervening molecular and tissue mechanisms
        are unresolved; the edge does not assert a measured direct causal step.
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Hepatic failure
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34298581
      reference_title: Expanding the genotypes and phenotypes for 19 rare diseases by exome sequencing performed in pediatric intensive care unit.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        Patient P21 presented similar phenotypes, such as persistent jaundice, decreased liver function,
        abnormal coagulation, and status epilepticus. She also had disseminated intravascular coagulation
        and a history of recurrent bronchopneumonia and seizures. The patient finally died of liver and
        respiratory failure.
      explanation: >-
        Clinical association of hepatic failure with COG4-CDG. The intervening molecular and tissue mechanisms
        are unresolved; the edge does not assert a measured direct causal step.
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Status epilepticus
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:34298581
      reference_title: Expanding the genotypes and phenotypes for 19 rare diseases by exome sequencing performed in pediatric intensive care unit.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        Patient P21 presented similar phenotypes, such as persistent jaundice, decreased liver function,
        abnormal coagulation, and status epilepticus. She also had disseminated intravascular coagulation
        and a history of recurrent bronchopneumonia and seizures. The patient finally died of liver and
        respiratory failure.
      explanation: >-
        Clinical association of status epilepticus with COG4-CDG. The intervening molecular and tissue
        mechanisms are unresolved; the edge does not assert a measured direct causal step.
    description: >-
      Clinical consequence of the causal COG4 disorder; intervening tissue mechanisms are unresolved.
  - target: Frontotemporal cerebral atrophy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19494034
      reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        At the age of 3 years the child presented with microcephaly, bilateral cerebral atrophy of the
        frontotemporal regions, a mild degree of ataxia, brisk, uncoordinated movements, absence of speech
        and moderate psychomotor delay.
      explanation: >-
        Clinical association with COG4-CDG; the intervening tissue mechanisms are unresolved.
  - target: Limb hypertonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19494034
      reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        Some dysmorphic features were noted, like a peculiar face (down sloping frontal area and thick
        hair) combined with axial hyponia, slight peripheral hypertonia and hyperreflexia.
      explanation: >-
        Clinical association with COG4-CDG; the intervening tissue mechanisms are unresolved.
  - target: Axial hypotonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19494034
      reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        Some dysmorphic features were noted, like a peculiar face (down sloping frontal area and thick
        hair) combined with axial hyponia, slight peripheral hypertonia and hyperreflexia.
      explanation: >-
        Clinical association with COG4-CDG; the intervening tissue mechanisms are unresolved.
  - target: Cognitive impairment
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/
      reference_title: Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY - GeneReviews® - NCBI Bookshelf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      directness: INDIRECT
      snippet: >-
        Features include severe cognitive impairment, seizures, hypotonia, liver cirrhosis, recurrent
        infections and early death. Less common features may include microcephaly, ataxia, and brisk uncoordinated
        movements
      explanation: >-
        The COG4 clinical association is described; intervening neurological mechanisms are unresolved.
- name: Reduced COG4 Expression
  biological_scale: MOLECULAR
  description: >-
    Reduced COG4 protein is documented in patient fibroblasts. In the founding p.Arg729Trp/deletion case,
    COG4-containing complexes still assembled at reduced abundance and several other subunit levels were
    affected. The p.Glu233Ter/p.Leu773Arg case showed reduced COG4 with other subunits unaffected. These
    are genotype- and system-specific observations, not a universal absence of complex assembly.
  gene:
    preferred_term: COG4
    term:
      id: hgnc:18620
      label: COG4
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: The resulting downregulation of COG4 expression additionally affects expression or stability of other lobe A subunits.
    explanation: >-
      Reduced COG4 and additional lobe A subunit effects were observed in the founding patient fibroblasts.
  - reference: PMID:21185756
    reference_title: Identification of the first COG-CDG patient of Indian origin.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: As a result, COG4 protein expression was dramatically reduced, while expression of the other subunits remained unaffected.
    explanation: >-
      A different patient genotype showed isolated COG4 reduction; the studies need not represent a biological
      contradiction.
  downstream:
  - target: Delayed Golgi retrograde transport
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21185756
      reference_title: Identification of the first COG-CDG patient of Indian origin.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        Importantly, patient fibroblasts exhibited a delay in Brefeldin A (BFA) induced retrograde transport,
        a common characteristic seen in COG deficiencies.
      explanation: >-
        COG4 reduction and transport delay coexist in patient fibroblasts; the intervening molecular events
        were not all resolved.
- name: Delayed Golgi retrograde transport
  biological_scale: CELLULAR
  description: >-
    Patient fibroblasts show delayed Brefeldin A-induced redistribution of Golgi proteins to the endoplasmic
    reticulum. This assay supports impaired retrograde trafficking but does not directly measure every
    intra-Golgi tethering step. In the founding patient, Golgi reassembly after BFA washout was not delayed.
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  biological_processes:
  - preferred_term: retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum
    modifier: DECREASED
    term:
      id: GO:0006890
      label: retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum
  evidence:
  - reference: PMID:21185756
    reference_title: Identification of the first COG-CDG patient of Indian origin.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Importantly, patient fibroblasts exhibited a delay in Brefeldin A (BFA) induced retrograde transport, a common characteristic seen in COG deficiencies.
    explanation: The direct cell-based measurement of the transport delay in patient material.
  downstream:
  - target: Proposed altered Golgi enzyme recycling
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19494034
      reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        Hence it is likely that the deficiency in tethering of intra-Golgi retrograde vesicles impairs
        recycling of the responsible enzymes and/or nucleotide-sugar transporters back to their correct
        cisternae.
      explanation: >-
        The authors propose enzyme or transporter recycling as the connection between tethering and glycosylation.
- name: Proposed altered Golgi enzyme recycling
  biological_scale: CELLULAR
  mechanism_confidence: HYPOTHETICAL
  description: >-
    Altered localization or residence time of glycosyltransferases and/or nucleotide-sugar transporters
    is proposed to explain abnormal glycan processing. In the 2011 patient, Core2 transferase localization
    was a mechanistic interpretation of glycan products, not a direct localization measurement.
  evidence:
  - reference: PMID:21185756
    reference_title: Identification of the first COG-CDG patient of Indian origin.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: INDIRECT
    snippet: >-
      COG4 deficiency in the patient fibroblasts might affect cellular localization as well as residence
      time of Core2 β1,6-GlcNAc transferase with protein cargo which could lead to decreased Core2 and
      more Core1 glycans.
    explanation: >-
      Explicitly proposed explanation for the O-glycan product distribution.
  downstream:
  - target: Abnormal N-glycan processing
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:19494034
      reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        Hence it is likely that the deficiency in tethering of intra-Golgi retrograde vesicles impairs
        recycling of the responsible enzymes and/or nucleotide-sugar transporters back to their correct
        cisternae.
      explanation: >-
        The authors propose enzyme or transporter recycling as the connection between tethering and glycosylation.
  - target: Abnormal O-glycan processing
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    evidence:
    - reference: PMID:21185756
      reference_title: Identification of the first COG-CDG patient of Indian origin.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: INDIRECT
      snippet: >-
        COG4 deficiency in the patient fibroblasts might affect cellular localization as well as residence
        time of Core2 β1,6-GlcNAc transferase with protein cargo which could lead to decreased Core2 and
        more Core1 glycans.
      explanation: >-
        Proposed localization/residence-time mechanism; the detailed causal intermediates remain uncertain.
- name: Abnormal N-glycan processing
  biological_scale: CELLULAR
  description: >-
    Golgi N-glycan processing can be abnormal, with reduced terminal sialylation and galactosylation in
    patient serum and increased mannose-binding lectin signal in engineered p.Arg729Trp cells. These findings
    vary by assay and genotype: two adult COG4 patients had initially normal second-line N-glycosylation
    analyses.
  biological_processes:
  - preferred_term: protein N-linked glycosylation
    term:
      id: GO:0006487
      label: protein N-linked glycosylation
    modifier: ABNORMAL
  evidence:
  - reference: PMID:21185756
    reference_title: Identification of the first COG-CDG patient of Indian origin.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: >-
      Analysis of serum N-glycans revealed deficiencies in both sialylation and galactosylation.
    explanation: >-
      Patient serum glycan finding.
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling of serum
      N-glycans showed mildly deficient galactosylation and sialylation, consistent with an impaired Golgi-mediated
      glycosylation.
    explanation: >-
      Independent clinical glycan profiling in the splice-variant families.
  - reference: PMID:34022244
    reference_title: 'Normal transferrin patterns in congenital disorders of glycosylation with Golgi homeostasis disruption: apolipoprotein C-III at the rescue!'
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      All results of second-line N-glycosylation analyses were initially normal.
    explanation: >-
      Refutes a universal expectation of abnormal N-glycan screening; this mixed report included two COG4
      siblings.
- name: Abnormal O-glycan processing
  biological_scale: CELLULAR
  description: >-
    Patient fibroblasts show altered O-glycan biosynthetic capacity on an artificial GAP acceptor, including
    increased Core1 structures and decreased extended Core2 glycans. Abnormal serum apoC-III O-glycoforms
    were detected in two adult siblings despite normal initial N-glycosylation screens.
  biological_processes:
  - preferred_term: protein O-linked glycosylation
    term:
      id: GO:0006493
      label: protein O-linked glycosylation
    modifier: ABNORMAL
  evidence:
  - reference: PMID:21185756
    reference_title: Identification of the first COG-CDG patient of Indian origin.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      HPLC analysis of purified, metabolically labeled, GAP molecules from patient fibroblasts revealed
      an increase in Galβ1,3GalNAc as well as Core1 monosialylated structures, with a decrease in extended
      Core2 based glycans.
    explanation: >-
      Patient-cell assay of artificial-acceptor glycan products, rather than a direct census of native
      O-glycoproteins.
  - reference: PMID:34022244
    reference_title: 'Normal transferrin patterns in congenital disorders of glycosylation with Golgi homeostasis disruption: apolipoprotein C-III at the rescue!'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      However, apoC-III 2-DE revealed characteristic "apoC-III1" pattern in P1 and specific "apoC-III0"
      patterns in P2 and P3.
    explanation: >-
      P2 and P3 are the COG4 siblings; the ATP6V0A2 result in P1 is not attributed to COG4.
- name: Altered Golgi ultrastructure
  biological_scale: CELLULAR
  description: >-
    Patient fibroblasts can show disorganized Golgi stacks, with some normal stacks retained in the founding
    COG4 case. This morphology was not reproduced by p.Arg729Trp constructs in the tested engineered RPE1
    and HEK293T backgrounds.
  biological_processes:
  - preferred_term: Golgi organization
    term:
      id: GO:0007030
      label: Golgi organization
    modifier: ABNORMAL
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      The overall Golgi integrity was substantially to very severely disrupted in all investigated cell lines
    explanation: >-
      TEM directly demonstrated disrupted Golgi integrity in the patient fibroblast panel, including COG4.
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Both the COG1- and COG4-deficient patient cells still show some stacks with a normal morphology,
      in contrast to the COG7 and COG8 patients.
    explanation: >-
      Comparative TEM documents heterogeneous Golgi morphology and retained normal stacks in COG4 fibroblasts.
  - reference: PMID:34603392
    reference_title: Development and Initial Characterization of Cellular Models for COG Complex-Related CDG-II Diseases.
    supports: REFUTE
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      The analysis revealed the Golgi stacks morphology and integrity were normal in all analyzed cell
      lines (Figure 4).
    explanation: >-
      Engineered point-mutant cells did not reproduce patient-fibroblast Golgi disruption.
phenotypes:
- category: Neurological
  name: Global developmental delay
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum proteins.
    explanation: Severe global disability with a progressive course is the leading feature.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:21185756
    reference_title: Identification of the first COG-CDG patient of Indian origin.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: >-
      Briefly, the patient suffered from profound developmental delay, hypotonia, failure to thrive, seizures,
      coagulopathy, liver cirrhosis and recurrent infections that were eventually fatal.
    explanation: >-
      Developmental delay is directly reported in this COG4 patient; no disease-wide frequency is inferred.
  description: >-
    Developmental delay ranges in severity across reported cases; severe progressive global disability
    is described in the later clinical synthesis.
- category: Neurological
  name: Secondary microcephaly
  description: >-
    Postnatal microcephaly is described in the COG4 clinical synthesis. The founding patient had normal
    early development and microcephaly by age three.
  phenotype_term:
    preferred_term: Secondary microcephaly
    term:
      id: HP:0005484
      label: Secondary microcephaly
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum proteins.
    explanation: Names post-natal microcephaly, which is the secondary form.
    quote_role: REVIEW_SYNTHESIS
- category: Neurological
  name: Brain atrophy
  phenotype_term:
    preferred_term: Brain atrophy
    term:
      id: HP:0012444
      label: Brain atrophy
    clinical_course: PROGRESSIVE
  evidence:
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum proteins.
    explanation: Brain atrophy is named directly.
    quote_role: REVIEW_SYNTHESIS
- category: Neurological
  name: Seizure
  description: >-
    Seizures are part of the clinical spectrum. The founding patient developed fever and irritability
    after a vaccination in the fourth month, followed by hospitalization for complex seizures. This
    single-case temporal sequence does not establish vaccination as a cause or a general disease trigger.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum proteins.
    explanation: Seizures are named directly.
    quote_role: REVIEW_SYNTHESIS
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Until the fourth month the boy had a normal development, but after a vaccination the child started
      fever and progressive irritability. He was hospitalized due to complex seizures, which were
      eventually suppressed by phenobarbital.
    explanation: >-
      Documents the founding patient's onset sequence and seizures, without establishing a causal trigger.
- category: Hematological
  name: Abnormality of coagulation
  description: >-
    Coagulopathy and reduced coagulation factors are reported. Disseminated intravascular coagulation
    occurred in one critically ill child; the relative contributions of glycosylation defects, liver disease
    and acute illness remain unresolved.
  phenotype_term:
    preferred_term: Abnormality of coagulation
    term:
      id: HP:0001928
      label: Abnormality of coagulation
  evidence:
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum proteins.
    explanation: Coagulopathy is named directly.
    quote_role: REVIEW_SYNTHESIS
- category: Hepatobiliary
  name: Abnormality of the liver
  phenotype_term:
    preferred_term: Abnormality of the liver
    term:
      id: HP:0001392
      label: Abnormality of the liver
    coarse_binding_basis: SOURCE_UNSPECIFIED
  evidence:
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum proteins.
    explanation: Liver involvement is named directly.
    quote_role: REVIEW_SYNTHESIS
  description: >-
    The 2026 clinical synthesis reports liver involvement without further specification in its abstract.
    Cirrhosis, elevated transaminases and hepatic failure are separately documented in earlier cases.
- category: Immunological
  name: Recurrent infections
  phenotype_term:
    preferred_term: Recurrent infections
    term:
      id: HP:0002719
      label: Recurrent infections
  evidence:
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: These findings and literature review define COG4-CDG(ar) as a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation of serum proteins.
    explanation: Recurrent infections are named directly.
    quote_role: REVIEW_SYNTHESIS
- category: Craniofacial
  name: Abnormal facial shape
  phenotype_term:
    preferred_term: Abnormal facial shape
    term:
      id: HP:0001999
      label: Abnormal facial shape
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Some dysmorphic features were noted, like a peculiar face (down sloping frontal area and thick hair)
      combined with axial hyponia, slight peripheral hypertonia and hyperreflexia.
    explanation: >-
      Case-specific facial dysmorphism; the quotation also contains the source spelling of axial hyponia.
  description: >-
    Facial dysmorphism was described in the founding patient, including a down-sloping frontal area; no
    frequency across COG4-CDG is established.
- category: Neurological
  name: Absent speech
  phenotype_term:
    preferred_term: Absent speech
    term:
      id: HP:0001344
      label: Absent speech
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      At the age of 3 years the child presented with microcephaly, bilateral cerebral atrophy of the frontotemporal
      regions, a mild degree of ataxia, brisk, uncoordinated movements, absence of speech and moderate
      psychomotor delay.
    explanation: >-
      Direct observation of absent speech in the COG4 patient, rather than a pooled all-COG ranking.
  description: >-
    Absence of speech was documented at age three in the founding patient.
- category: Neurological
  name: Hypotonia
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  evidence:
  - reference: PMID:21185756
    reference_title: Identification of the first COG-CDG patient of Indian origin.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Briefly, the patient suffered from profound developmental delay, hypotonia, failure to thrive, seizures, coagulopathy, liver cirrhosis and recurrent infections that were eventually fatal.
    explanation: Case-level description naming hypotonia. No frequency is asserted because the support is a single patient rather than a series percentage.
    quote_role: BACKGROUND
- category: Growth
  name: Failure to thrive
  phenotype_term:
    preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  evidence:
  - reference: PMID:21185756
    reference_title: Identification of the first COG-CDG patient of Indian origin.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Briefly, the patient suffered from profound developmental delay, hypotonia, failure to thrive, seizures, coagulopathy, liver cirrhosis and recurrent infections that were eventually fatal.
    explanation: Case-level description naming failure to thrive. No frequency is asserted for the same reason as hypotonia.
    quote_role: BACKGROUND
- name: Cirrhosis
  category: Hepatobiliary
  description: >-
    Liver cirrhosis was reported in the second molecularly characterized COG4 patient.
  phenotype_term:
    preferred_term: Cirrhosis
    term:
      id: HP:0001394
      label: Cirrhosis
  evidence:
  - reference: PMID:21185756
    reference_title: Identification of the first COG-CDG patient of Indian origin.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    directness: DIRECT
    snippet: >-
      Briefly, the patient suffered from profound developmental delay, hypotonia, failure to thrive, seizures,
      coagulopathy, liver cirrhosis and recurrent infections that were eventually fatal.
    explanation: >-
      Liver cirrhosis was reported in the second molecularly characterized COG4 patient.
- name: Elevated hepatic transaminase
  category: Hepatobiliary
  description: >-
    Elevated transaminases were measured in the founding patient.
  phenotype_term:
    preferred_term: Elevated circulating hepatic transaminase concentration
    term:
      id: HP:0002910
      label: Elevated circulating hepatic transaminase concentration
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Blood tests revealed increased serum transaminases, alkaline phosphatases and LDH cholesterol levels,
      while the platelet counts were down.
    explanation: >-
      Elevated transaminases were measured in the founding patient.
- name: Thrombocytopenia
  category: Hematological
  description: >-
    Low platelet counts were reported in the founding patient.
  phenotype_term:
    preferred_term: Thrombocytopenia
    term:
      id: HP:0001873
      label: Thrombocytopenia
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Blood tests revealed increased serum transaminases, alkaline phosphatases and LDH cholesterol levels,
      while the platelet counts were down.
    explanation: >-
      Low platelet counts were reported in the founding patient.
- name: Hyperreflexia
  category: Neurological
  description: >-
    Hyperreflexia was documented in the founding patient.
  phenotype_term:
    preferred_term: Hyperreflexia
    term:
      id: HP:0001347
      label: Hyperreflexia
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Some dysmorphic features were noted, like a peculiar face (down sloping frontal area and thick hair)
      combined with axial hyponia, slight peripheral hypertonia and hyperreflexia.
    explanation: >-
      Hyperreflexia was documented in the founding patient.
- name: Ataxia
  category: Neurological
  description: >-
    Mild ataxia was observed at age three in the founding patient.
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      At the age of 3 years the child presented with microcephaly, bilateral cerebral atrophy of the frontotemporal
      regions, a mild degree of ataxia, brisk, uncoordinated movements, absence of speech and moderate
      psychomotor delay.
    explanation: >-
      Mild ataxia was observed at age three in the founding patient.
- name: Hepatic failure
  category: Hepatobiliary
  description: >-
    Liver failure was a terminal complication in patient P21; this observation does not establish its
    frequency or isolate its cause from concurrent critical illness.
  phenotype_term:
    preferred_term: Hepatic failure
    term:
      id: HP:0001399
      label: Hepatic failure
  evidence:
  - reference: PMID:34298581
    reference_title: Expanding the genotypes and phenotypes for 19 rare diseases by exome sequencing performed in pediatric intensive care unit.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Patient P21 presented similar phenotypes, such as persistent jaundice, decreased liver function,
      abnormal coagulation, and status epilepticus. She also had disseminated intravascular coagulation
      and a history of recurrent bronchopneumonia and seizures. The patient finally died of liver and
      respiratory failure.
    explanation: >-
      Liver failure was a terminal complication in patient P21; this observation does not establish its
      frequency or isolate its cause from concurrent critical illness.
- name: Status epilepticus
  category: Neurological
  description: >-
    Status epilepticus was reported in patient P21 in the pediatric intensive care cohort.
  phenotype_term:
    preferred_term: Status epilepticus
    term:
      id: HP:0002133
      label: Status epilepticus
  evidence:
  - reference: PMID:34298581
    reference_title: Expanding the genotypes and phenotypes for 19 rare diseases by exome sequencing performed in pediatric intensive care unit.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Patient P21 presented similar phenotypes, such as persistent jaundice, decreased liver function,
      abnormal coagulation, and status epilepticus. She also had disseminated intravascular coagulation
      and a history of recurrent bronchopneumonia and seizures. The patient finally died of liver and
      respiratory failure.
    explanation: >-
      Status epilepticus was reported in patient P21 in the pediatric intensive care cohort.
- name: Frontotemporal cerebral atrophy
  category: Neurological
  phenotype_term:
    preferred_term: Frontotemporal cerebral atrophy
    term:
      id: HP:0006892
      label: Frontotemporal cerebral atrophy
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      At the age of 3 years the child presented with microcephaly, bilateral cerebral atrophy of the frontotemporal
      regions, a mild degree of ataxia, brisk, uncoordinated movements, absence of speech and moderate
      psychomotor delay.
    explanation: >-
      Case-level observation in the founding COG4 patient.
- name: Limb hypertonia
  category: Neurological
  phenotype_term:
    preferred_term: Limb hypertonia
    term:
      id: HP:0002509
      label: Limb hypertonia
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Some dysmorphic features were noted, like a peculiar face (down sloping frontal area and thick hair)
      combined with axial hyponia, slight peripheral hypertonia and hyperreflexia.
    explanation: >-
      Case-level observation in the founding COG4 patient.
- name: Axial hypotonia
  category: Neurological
  phenotype_term:
    preferred_term: Axial hypotonia
    term:
      id: HP:0008936
      label: Axial hypotonia
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Some dysmorphic features were noted, like a peculiar face (down sloping frontal area and thick hair)
      combined with axial hyponia, slight peripheral hypertonia and hyperreflexia.
    explanation: >-
      Case-level observation in the founding COG4 patient. The source spells axial hypotonia as axial
      hyponia.
- name: Cognitive impairment
  category: Neurological
  description: >-
    Severe cognitive impairment is described in the COG4-specific section of the historical GeneReviews
    overview.
  phenotype_term:
    preferred_term: Cognitive impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/
    reference_title: Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: DIRECT
    snippet: >-
      Features include severe cognitive impairment, seizures, hypotonia, liver cirrhosis, recurrent infections
      and early death. Less common features may include microcephaly, ataxia, and brisk uncoordinated
      movements
    explanation: >-
      The COG4-specific paragraph of the retired overview supports cognitive impairment, without supplying
      a reliable frequency estimate. Later primary reports include survival to adulthood.
experimental_models:
- name: COG4-CDG patient fibroblasts
  experimental_model_type: PRIMARY_CELL_CULTURE
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  description: >-
    Primary fibroblasts from the founding compound-heterozygous patients model COG4 protein abundance,
    BFA-induced retrograde trafficking and glycan biosynthesis. Wild-type COG4 viral complementation did
    not restore a normal BFA response in the tested patient cells. Increasing COG4 expression also impaired
    the BFA response in control fibroblasts in the founding study.
  modeled_mechanisms:
  - target: Delayed Golgi retrograde transport
    relationship: RECAPITULATES
    model_scale: CELLULAR
    fidelity: MODERATE
    limitations: >-
      BFA redistributes Golgi proteins pharmacologically; the assay does not isolate every physiological
      tethering or fusion step, and fibroblasts do not establish organ-specific mechanisms.
    divergences:
    - divergence_type: BOUNDARY_OMISSION
      materiality: QUALIFYING
      description: >-
        Cultured cells lack the neuronal, hepatic and systemic context required to explain the clinical
        disorder.
    evidence:
    - reference: PMID:21185756
      reference_title: Identification of the first COG-CDG patient of Indian origin.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: >-
        Importantly, patient fibroblasts exhibited a delay in Brefeldin A (BFA) induced retrograde transport,
        a common characteristic seen in COG deficiencies.
      explanation: >-
        Direct patient-cell transport readout.
  - target: Abnormal O-glycan processing
    relationship: PARTIALLY_RECAPITULATES
    model_scale: CELLULAR
    fidelity: MODERATE
    limitations: >-
      GAP is an artificial acceptor of glycan biosynthesis; products mimic glycan chains but do not enumerate
      native glycoprotein substrates.
    evidence:
    - reference: PMID:21185756
      reference_title: Identification of the first COG-CDG patient of Indian origin.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: >-
        HPLC analysis of purified, metabolically labeled, GAP molecules from patient fibroblasts revealed
        an increase in Galβ1,3GalNAc as well as Core1 monosialylated structures, with a decrease in extended
        Core2 based glycans.
      explanation: >-
        Patient-derived biosynthetic-capacity readout.
  evidence:
  - reference: PMID:21185756
    reference_title: Identification of the first COG-CDG patient of Indian origin.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      To our surprise transduction of patient fibroblasts with the wild-type COG4 did not restore the
      normal BFA response even using various viral titers or infection times.
    explanation: >-
      Failed complementation is an experimental limitation, not evidence of an effective gene therapy.
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Surprisingly, stable transduction of control cells with COG4 (thereby doubling expression levels)
      resulted in a retrograde trafficking defect, reminiscent of that observed in patient cells.
    explanation: >-
      Increasing COG4 expression impaired the control-cell trafficking assay, limiting a simple dosage-rescue
      interpretation.
- name: COG4-knockout RPE1 and HEK293T cells complemented with p.Arg729Trp
  experimental_model_type: CELL_LINE
  description: >-
    CRISPR COG4 knockouts were complemented by lentiviral myc-tagged wild-type or mutant COG4 under a
    cloned COG4 promoter. The p.Arg729Trp constructs restored many knockout abnormalities while retaining
    an N-glycosylation defect. These are complemented knockout backgrounds, not endogenous-locus patient-genotype
    knock-ins.
  modeled_mechanisms:
  - target: Abnormal N-glycan processing
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    model_scale: CELLULAR
    description: >-
      p.Arg729Trp cells show increased GNL binding consistent with abnormal N-glycosylation.
    limitations: >-
      Tagged constructs in engineered non-patient backgrounds; lectin binding is a glycan-class readout
      and does not reproduce every serum glycan or clinical phenotype.
    divergences:
    - divergence_type: BOUNDARY_OMISSION
      materiality: QUALIFYING
      description: >-
        Cultured cells lack the neuronal, hepatic and systemic context required to explain the clinical
        disorder.
    evidence:
    - reference: PMID:34603392
      reference_title: Development and Initial Characterization of Cellular Models for COG Complex-Related CDG-II Diseases.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: >-
        In contrast, binding of GNL to plasma membrane of non-permeabilized cells was increased in both
        mutant cell lines, but most significantly in cells expressing COG4-R729W (Figures 6A,B, Supplementary
        Figure S3B).
      explanation: >-
        Direct lectin readout in engineered p.Arg729Trp cells.
  - target: Altered Golgi ultrastructure
    relationship: FAILS_TO_RECAPITULATE
    model_scale: CELLULAR
    limitations: >-
      Normal Golgi stack morphology in these engineered point-mutant cells contrasts with patient-fibroblast
      disruption.
    evidence:
    - reference: PMID:34603392
      reference_title: Development and Initial Characterization of Cellular Models for COG Complex-Related CDG-II Diseases.
      supports: REFUTE
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: >-
        The analysis revealed the Golgi stacks morphology and integrity were normal in all analyzed cell
        lines (Figure 4).
      explanation: >-
        Negative morphology result prevents treating this model as reproducing all patient-cell defects.
  evidence:
  - reference: PMID:34603392
    reference_title: Development and Initial Characterization of Cellular Models for COG Complex-Related CDG-II Diseases.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Using a combination of CRISPR/Cas9 and lentiviral transduction technologies, both myc-tagged wild-type and mutant (G516R and R729W) COG4 proteins were expressed under the endogenous COG4 promoter.
    explanation: >-
      Documents knockout plus lentiviral complementation with promoter-controlled constructs; it does
      not by itself exclude expression-system artifacts.
  - reference: PMID:34603392
    reference_title: Development and Initial Characterization of Cellular Models for COG Complex-Related CDG-II Diseases.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Expression of wild-type and mutant COG4 rescued stability and glycosylation of all three tested
      proteins (Figure 2A, Supplementary Figure S1A).
    explanation: >-
      The proteins are B4GalT1, Lamp2 and TMEM165 in the preceding experimental description.
  - reference: PMID:34603392
    reference_title: Development and Initial Characterization of Cellular Models for COG Complex-Related CDG-II Diseases.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      This result indicates the investigated COG4 mutations do not significantly affect GS15 localization
      or stability.
    explanation: >-
      A measured negative result for the tested point-mutant cell lines.
  - reference: PMID:34603392
    reference_title: Development and Initial Characterization of Cellular Models for COG Complex-Related CDG-II Diseases.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      WB revealed a significant increase in core proteins of HSPGs accumulation on the cell surface of
      both COG4-G516R and COG4-R729W mutant cell lines.
    explanation: >-
      Shared HSPG phenotype does not establish a unique clinical mechanism.
  findings:
  - statement: p.Arg729Trp restored B4GalT1 abundance and Lamp2/TMEM165 glycosylation in the tested knockout backgrounds.
    evidence:
    - reference: PMID:34603392
      reference_title: Development and Initial Characterization of Cellular Models for COG Complex-Related CDG-II Diseases.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: >-
        Expression of wild-type and mutant COG4 rescued stability and glycosylation of all three tested
        proteins (Figure 2A, Supplementary Figure S1A).
      explanation: >-
        The proteins are B4GalT1, Lamp2 and TMEM165 in the preceding experimental description.
  - statement: GS15 localization and abundance were not significantly altered in the rescued point-mutant lines.
    evidence:
    - reference: PMID:34603392
      reference_title: Development and Initial Characterization of Cellular Models for COG Complex-Related CDG-II Diseases.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: >-
        This result indicates the investigated COG4 mutations do not significantly affect GS15 localization
        or stability.
      explanation: >-
        A measured negative result for the tested point-mutant cell lines.
  - statement: Heparan sulfate proteoglycan core-protein accumulation was increased in p.Arg729Trp and p.Gly516Arg lines; this alone did not explain the distinct Saul-Wilson phenotype.
    evidence:
    - reference: PMID:34603392
      reference_title: Development and Initial Characterization of Cellular Models for COG Complex-Related CDG-II Diseases.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      directness: DIRECT
      snippet: >-
        WB revealed a significant increase in core proteins of HSPGs accumulation on the cell surface
        of
        both COG4-G516R and COG4-R729W mutant cell lines.
      explanation: >-
        Shared HSPG phenotype does not establish a unique clinical mechanism.
diagnosis:
- name: Serum N-glycan mass spectrometry
  description: >-
    Serum N-glycan mass spectrometry can reveal deficient galactosylation and sialylation, as in the 2026
    families. A normal result does not exclude COG4-CDG: both transferrin and broader second-line N-glycosylation
    analyses were initially normal in two adult siblings.
  evidence:
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling of serum N-glycans showed mildly deficient galactosylation and sialylation, consistent with an impaired Golgi-mediated glycosylation.
    explanation: The glycan assay and the abnormality it detects in this disorder.
  - reference: PMID:34022244
    reference_title: 'Normal transferrin patterns in congenital disorders of glycosylation with Golgi homeostasis disruption: apolipoprotein C-III at the rescue!'
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      All results of second-line N-glycosylation analyses were initially normal.
    explanation: >-
      Limits diagnostic sensitivity; an abnormal apoC-III O-glycan pattern provided additional evidence
      in the COG4 siblings.
- name: Serum IgG N-glycosylation analysis
  description: >-
    Serum IgG N-glycan abnormalities analogous to total serum findings were reported in the 2026 families.
    Diagnostic sensitivity, specificity and comparative accessibility were not established by that observation.
  evidence:
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: As a novel finding, N-glycosylation study of serum IgG showed analogous N-glycan anomalies.
    explanation: Documents the IgG glycan finding as newly reported in this disorder.
- name: Serum transferrin isoelectric focusing
  description: >-
    Transferrin isoelectric focusing can show an abnormal type 2 pattern, as in the founding COG4 patient.
    Screening can also be normal in affected individuals and therefore cannot by itself exclude the disorder.
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Because CDG was suspected, isoelectric focusing of serum transferrin was performed and showed a type 2 pattern
    explanation: >-
      Documents an abnormal transferrin screen in the founding COG4-CDG patient.
  - reference: PMID:34022244
    reference_title: 'Normal transferrin patterns in congenital disorders of glycosylation with Golgi homeostasis disruption: apolipoprotein C-III at the rescue!'
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: We identified three cases of congenital disorders of glycosylation (CDG) with Golgi homeostasis disruption, one ATP6V0A2-CDG and two COG4-CDG, with normal transferrin screening analyses.
    explanation: 'Graded REFUTE against the implicit claim that transferrin screening detects this disorder: the cited cases are COG4-CDG patients in whom it did not.'
- name: Apolipoprotein C-III two-dimensional electrophoresis
  description: >-
    Two-dimensional electrophoresis of mucin core 1 O-glycosylated apoC-III detected abnormal apoC-III0
    patterns in two COG4 siblings whose initial N-glycosylation analyses were normal. The result helped
    reclassify their homozygous COG4 variant as likely pathogenic; performance across all COG4 genotypes
    remains uncertain.
  evidence:
  - reference: PMID:34022244
    reference_title: 'Normal transferrin patterns in congenital disorders of glycosylation with Golgi homeostasis disruption: apolipoprotein C-III at the rescue!'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: However, apoC-III 2-DE revealed characteristic "apoC-III1" pattern in P1 and specific "apoC-III0" patterns in P2 and P3.
    explanation: Reports what the assay showed in the patients, including the two COG4-CDG cases, which is the claim this entry makes.
  - reference: PMID:34022244
    reference_title: 'Normal transferrin patterns in congenital disorders of glycosylation with Golgi homeostasis disruption: apolipoprotein C-III at the rescue!'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Furthermore, they show the potential of apoC-III 2-DE in diagnosing this type of CDG, with highly specific patterns in COG-CDG.
    explanation: States the diagnostic value of the assay in COG-CDG specifically.
- name: COG4 molecular and RNA analysis
  description: >-
    Identify biallelic COG4 variants through sequencing with deletion analysis where indicated, and assess
    segregation. RNA studies can resolve splice consequences. Biochemical evidence can support interpretation
    of uncertain variants even with normal transferrin screening.
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      We report a new CDG-II patient harbouring a p.R729W missense mutation in COG4 combined with a submicroscopical
      deletion.
    explanation: >-
      A deletion in trans to a sequence variant shows why a negative second sequence allele does not exhaust
      molecular testing.
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Whole transcriptome sequencing and reverse transcriptase PCR from peripheral blood detected an aberrant
      COG4 transcript which features skipping of exon 12 and results in a frameshift, predicted to introduce
      a premature termination codon.
    explanation: >-
      RNA studies demonstrated aberrant splicing after exome identification of the intronic variant.
  - reference: PMID:34022244
    reference_title: 'Normal transferrin patterns in congenital disorders of glycosylation with Golgi homeostasis disruption: apolipoprotein C-III at the rescue!'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      In P2 and P3, this allowed reclassifying the variant as likely pathogenic according to ACMG guidelines.
    explanation: >-
      In context, abnormal apoC-III patterns supported interpretation of the homozygous COG4 variant.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/
    reference_title: Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
    snippet: >-
      If previous biochemical testing is not diagnostic for or suggestive of a particular CDG, molecular
      testing approaches most often involve use of a ... multigene panel ... or ... more ... comprehensive
      ... genomic ... testing
    explanation: >-
      Historical group-level diagnostic guidance, supported here by the COG4-specific exome and RNA studies.
differential_diagnoses:
- name: Saul-Wilson syndrome (COG4, dominant)
  description: >-
    Saul-Wilson syndrome is a skeletal dysplasia with primordial dwarfism caused by recurrent heterozygous
    de novo p.Gly516Arg. Patient fibroblasts showed preserved COG4 abundance and accelerated retrograde
    recycling, contrasting with the reduced abundance and delayed recycling documented in recessive COG4-CDG
    fibroblasts.
  evidence:
  - reference: PMID:30290151
    reference_title: A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: All affected subjects harbored heterozygous de novo variants in COG4, giving rise to the same recurrent amino acid substitution (p.Gly516Arg).
    explanation: Establishes the dominant, single-recurrent-allele genetics that separate Saul-Wilson from recessive COG4-CDG.
  - reference: PMID:30290151
    reference_title: A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation.
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: Affected individuals' fibroblasts, whose COG4 mRNA and protein were not decreased, exhibited delayed anterograde vesicular trafficking from the ER to the Golgi and accelerated retrograde vesicular recycling from the Golgi to the ER.
    explanation: 'The mechanistic contrast that carries the lump/split argument: normal COG4 levels and accelerated rather than delayed retrograde transport.'
- name: Lobe B COG-CDG (COG5-8)
  description: >-
    Other COG-subunit disorders share trafficking and glycosylation abnormalities and require gene-specific
    molecular diagnosis. A historical lobe A versus lobe B severity hypothesis compared mutation classes
    and residual expression; it does not establish that every lobe B disorder is milder or provide individual
    COG4 prognosis.
  evidence:
  - reference: PMID:28848061
    reference_title: 'Hypothesis: lobe A (COG1-4)-CDG causes a more severe phenotype than lobe B (COG5-8)-CDG.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Second, nearly all of the 27 patients with lobe B COG-CDG had bi-allelic truncating mutations, as compared with only one of the six patients with lobe A COG-CDG.
    explanation: >-
      Historical comparison of mutation classes across COG disorders, not a validated individual severity
      prediction.
    quote_role: REVIEW_SYNTHESIS
discussions:
- discussion_id: cog4cdg_glycan_to_organ_gap
  kind: KNOWLEDGE_GAP
  prompt: Which glycoproteins and tissue processes connect COG4 dysfunction to neurological and hepatic disease?
  attaches_to:
  - pathophysiology#Biallelic COG4 dysfunction
  - pathophysiology#Abnormal N-glycan processing
  - pathophysiology#Abnormal O-glycan processing
  rationale: >-
    Clinical outcome edges have unknown intermediates. Mild or initially normal serum N-glycan assays
    can accompany severe disease, and the cited studies do not identify a single glycoprotein lesion explaining
    the organ pattern.
- discussion_id: cog4cdg_conflicting_subunit_effects
  kind: KNOWLEDGE_GAP
  prompt: How do genotype and cellular background determine COG-complex abundance and Golgi morphology?
  attaches_to:
  - pathophysiology#Reduced COG4 Expression
  - pathophysiology#Altered Golgi ultrastructure
  rationale: >-
    The two founding patient-cell studies differ in effects on other COG subunits. Engineered p.Arg729Trp
    cells retain normal COG4 levels and Golgi morphology. These observations may reflect allele dosage,
    expression system or cellular background; they do not establish a universal isolated quantitative
    lesion.
- discussion_id: cog4cdg_autophagy_hypothesis
  kind: KNOWLEDGE_GAP
  prompt: Does altered autophagy contribute to recessive COG4-CDG?
  attaches_to:
  - pathophysiology#Biallelic COG4 dysfunction
  rationale: >-
    A pooled all-COG-CDG phenotype study proposed an autophagy connection to episodic fever. It did not
    demonstrate reduced autophagic flux or a fever mechanism in COG4 patients. Pooled phenotype frequencies
    and specificity rankings cannot establish COG4-specific rates.
  evidence:
  - reference: PMID:31804708
    reference_title: 'Hypothesis: determining phenotypic specificity facilitates understanding of pathophysiology in rare genetic disorders.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    directness: INDIRECT
    snippet: >-
      The links between episodic fever and autophagy, and autophagy and the COG complex suggest that episodic
      fever in COG‐CDG patients, unlike other COG‐CDG phenotypic features caused by the disrupted glycosylation
      process, might be caused by disruption of its function in the autophagy pathway. The veracity of
      this hypothesis remains to be further elucidated.
    explanation: >-
      The authors explicitly identify the autophagy-fever account as an unresolved hypothesis.
- discussion_id: cog4cdg_residual_function
  kind: KNOWLEDGE_GAP
  prompt: How much residual COG4 function is required for survival?
  attaches_to:
  - pathophysiology#Biallelic COG4 dysfunction
  rationale: >-
    A historical lobe A mutation-spectrum analysis proposed that near-total loss might be nonviable. The
    later homozygous splice variant produces a frameshifted transcript, but the available RNA result does
    not quantify residual functional protein. Neither study establishes complete-null human viability
    or a general prognostic rule.
  evidence:
  - reference: PMID:28848061
    reference_title: 'Hypothesis: lobe A (COG1-4)-CDG causes a more severe phenotype than lobe B (COG5-8)-CDG.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
    snippet: >-
      This represents a frequency gap which suggests that bi-allelic truncating mutations in COG lobe
      A genes might be non-viable.
    explanation: >-
      Mutation-spectrum hypothesis across lobe A genes; not a direct COG4 viability experiment.
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Whole transcriptome sequencing and reverse transcriptase PCR from peripheral blood detected an aberrant
      COG4 transcript which features skipping of exon 12 and results in a frameshift, predicted to introduce
      a premature termination codon.
    explanation: >-
      Measured aberrant transcript with predicted premature stop, without a cited protein-null assay.
treatments:
- name: Phenobarbital for seizures
  description: >-
    Phenobarbital suppressed complex seizures in the founding patient. This is a single-patient symptomatic
    response; no comparative efficacy or disease-modifying effect is established.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Anticonvulsant Therapy
    term:
      id: NCIT:C64172
      label: Anticonvulsant Therapy
    therapeutic_agent:
    - preferred_term: phenobarbital
      term:
        id: CHEBI:8069
        label: phenobarbital
  target_phenotypes:
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  evidence:
  - reference: PMID:19494034
    reference_title: Golgi function and dysfunction in the first COG4-deficient CDG type II patient.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      He was hospitalized due to complex seizures, which were eventually suppressed by phenobarbital.
    explanation: >-
      Direct clinical treatment response in one patient.
- name: Nutritional and developmental support
  action_category: THERAPEUTIC
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  description: >-
    The retired GeneReviews overview recommends nutritional support for failure to thrive and occupational,
    physical and speech therapy for developmental delay across N-linked and multiple-pathway CDGs. These
    are general supportive-care recommendations applicable to the corresponding COG4 manifestations, rather
    than COG4 intervention-trial results.
  target_phenotypes:
  - preferred_term: Failure to thrive
    term:
      id: HP:0001508
      label: Failure to thrive
  - preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/
    reference_title: Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
    snippet: >-
      Some children require placement of a nasogastric tube or gastrostomy tube for nutritional support
      until oral motor skills improve.
    explanation: >-
      Historical group-level nutritional support; does not establish COG4-specific tube-feeding outcomes.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/
    reference_title: Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
    snippet: >-
      Occupational therapy, physical therapy, and speech therapy should be instituted. As the developmental
      gap widens between children with CDG and their unaffected peers, parents, educators, and therapists
      need continued counseling and support.
    explanation: >-
      General developmental-care recommendation in the retired overview, not a COG4-specific efficacy
      study.
- name: Hepatic and coagulation surveillance
  action_category: MONITORING
  treatment_term:
    preferred_term: Clinical Evaluation
    term:
      id: NCIT:C124351
      label: Clinical Evaluation
  description: >-
    The retired group-level overview includes liver-function and coagulation-factor surveillance, with
    hematology assessment before surgery. This is general CDG guidance for manifestations documented in
    COG4-CDG; the surveillance interval has not been validated specifically in COG4 patients.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/
    reference_title: Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
    snippet: >-
      Consultation with a hematologist is recommended to document the pro- and anti- clotting factor levels
      and coagulation status.
    explanation: >-
      General coagulation assessment recommendation from the retired CDG overview.
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/
    reference_title: Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
    snippet: >-
      Liver function tests; thyroid panel; serum concentrations of the clotting factors protein C, protein
      S, factor IX, and antithrombin III
    explanation: >-
      The source lists these under annual surveillance for the broad CDG group; only hepatic/coagulation
      monitoring is modeled here.
- name: Genetic counseling and reproductive planning
  action_category: COUNSELING_INFORMATIONAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  description: >-
    Counseling includes segregation and carrier assessment, conditional recurrence risk and reproductive
    options. The historical overview states that prenatal and preimplantation testing become possible
    after identification of familial pathogenic variants. A de novo allele in one COG4 family means parental
    carrier status must be established rather than assumed.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/
    reference_title: Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
    snippet: >-
      Once the ... pathogenic variant ... (s) have been identified in the family, ... prenatal testing
      ... for a pregnancy at increased risk and ... preimplantation genetic testing ... for a ... congenital
      ... disorder of N-linked glycosylation or multiple pathway are possible.
    explanation: >-
      General molecularly defined CDG counseling, applicable once familial COG4 variants are established.
- name: Medication precautions with hepatic involvement
  action_category: COUNSELING_INFORMATIONAL
  treatment_term:
    preferred_term: Counseling
    term:
      id: NCIT:C61547
      label: Counseling
  description: >-
    The retired overview advises caution with acetaminophen and other hepatically metabolized agents.
    This is historical general CDG guidance, not evidence that all such agents are contraindicated in
    COG4-CDG; medication decisions require individual hepatic assessment.
  evidence:
  - reference: url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/
    reference_title: Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY - GeneReviews® - NCBI Bookshelf
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    directness: INDIRECT
    snippet: >-
      Acetominophen and other agents metabolized by the liver should be used with caution.
    explanation: >-
      Historical general medication precaution; the source spells acetaminophen as acetominophen. It does
      not report a COG4-specific adverse-drug study.
variants:
- name: COG4 c.1647+5G>A
  gene:
    preferred_term: COG4
    term:
      id: hgnc:18620
      label: COG4
  variant_type: single nucleotide variant
  genomic_contexts:
  - intron
  description: >-
    Homozygous splice-altering variant identified in four affected individuals from two Italian families.
    Blood transcriptome sequencing and RT-PCR demonstrated exon 12 skipping. The resulting frameshift
    predicts a premature termination codon; protein abundance and nonsense-mediated decay were not established
    by the quoted RNA result.
  evidence:
  - reference: PMID:42202558
    reference_title: A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Whole transcriptome sequencing and reverse transcriptase PCR from peripheral blood detected an aberrant
      COG4 transcript which features skipping of exon 12 and results in a frameshift, predicted to introduce
      a premature termination codon.
    explanation: >-
      Separates the measured blood RNA splice defect from the predicted coding consequence.
animal_models:
- species: Danio rerio
  genotype: cog4 b1312 homozygous null
  description: >-
    The b1312 allele is a 13-base-pair exon 12 deletion with a frameshift and premature stop. Null larvae
    showed delayed epithelial projection growth and reduced extracellular-matrix secretion during semicircular-canal
    development. This gene-loss model probes Cog4 function; its ear phenotype does not establish hearing
    impairment in recessive human COG4-CDG.
  modeled_mechanisms:
  - target: Biallelic COG4 dysfunction
    relationship: PERTURBS
    model_scale: ORGANISM
    limitations: >-
      Complete zebrafish gene loss differs from residual-function human alleles. The study examines ear
      morphogenesis and does not reproduce or quantify the human multisystem phenotype.
    divergences:
    - divergence_type: BOUNDARY_OMISSION
      materiality: QUALIFYING
      description: Larval inner-ear developmental readouts do not establish the neurological and hepatic course of human COG4-CDG.
    evidence:
    - reference: PMID:30287385
      reference_title: Cog4 is required for protrusion and extension of the epithelium in the developing semicircular canals.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: BACKGROUND
      directness: DIRECT
      snippet: >-
        The cog4b1312 allele is a 13 bp deletion in exon 12 of cog4. The mutation introduces a frameshift
        followed by an early stop codon (Ferreira et al., in press).
      explanation: >-
        Defines the gene-loss perturbation used in the developmental study.
  evidence:
  - reference: PMID:30287385
    reference_title: Cog4 is required for protrusion and extension of the epithelium in the developing semicircular canals.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    directness: DIRECT
    snippet: >-
      Here, we show that formation of the pillars is delayed and that secretion of extracellular matrix
      components (ECM) is impaired in cog4-/- mutants.
    explanation: >-
      Direct developmental observations in null zebrafish.

📚

References & Deep Research

References

13

PMID:42202558

A splice-altering intronic variant in two multiplex families refines autosomal recessive COG4-related congenital disorder of glycosylation.

No top-level findings curated for this source.

PMID:31804708

Hypothesis: determining phenotypic specificity facilitates understanding of pathophysiology in rare genetic disorders.

No top-level findings curated for this source.

PMID:19494034

Golgi function and dysfunction in the first COG4-deficient CDG type II patient.

No top-level findings curated for this source.

PMID:21185756

Identification of the first COG-CDG patient of Indian origin.

No top-level findings curated for this source.

PMID:34022244

Normal transferrin patterns in congenital disorders of glycosylation with Golgi homeostasis disruption: apolipoprotein C-III at the rescue!

No top-level findings curated for this source.

PMID:34603392

Development and Initial Characterization of Cellular Models for COG Complex-Related CDG-II Diseases.

No top-level findings curated for this source.

PMID:19651599

Structural basis for a human glycosylation disorder caused by mutation of the COG4 gene.

No top-level findings curated for this source.

PMID:34298581

Expanding the genotypes and phenotypes for 19 rare diseases by exome sequencing performed in pediatric intensive care unit.

No top-level findings curated for this source.

PMID:30287385

Cog4 is required for protrusion and extension of the epithelium in the developing semicircular canals.

No top-level findings curated for this source.

PMID:30290151

A Recurrent De Novo Heterozygous COG4 Substitution Leads to Saul-Wilson Syndrome, Disrupted Vesicular Trafficking, and Altered Proteoglycan Glycosylation.

No top-level findings curated for this source.

PMID:28848061

Hypothesis: lobe A (COG1-4)-CDG causes a more severe phenotype than lobe B (COG5-8)-CDG.

No top-level findings curated for this source.

PMID:20301507

Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY.

No top-level findings curated for this source.

url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/

Congenital Disorders of N-Linked Glycosylation and Multiple Pathway Overview – RETIRED CHAPTER, FOR HISTORICAL REFERENCE ONLY - GeneReviews® - NCBI Bookshelf

No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (2)

Review COG4-CDG clinical evidence, glycosylation mechanisms and model limits · 2026-10-03T04:01:07Z · View source

Reviewed the complete COG4-CDG entry, its three existing CREATE/EDIT history records, and the OpenScientist deep-research report against cached and newly retrieved sources. Preflight confirmed MONDO:0013281, OMIM:613489 and COG4; the report's erroneous suggested HGNC identifier was not used. Rebased the review branch on origin/main before work. This inherited disorder has no prior REVIEW and is within the campaign excluding infectious/environmental disorders. The Saul-Wilson differential remains a separate dominant disorder. Major findings and corrections: - Removed all-COG-CDG pooled phenotype frequencies, unsupported COG4 hearing impairment/recurrent-fever assignments and the pooled intellectual-disability evidence. Retained disease-specific absent speech and facial dysmorphism with founding-case evidence; added cognitive impairment from the COG4-specific historical GeneReviews paragraph without a frequency band. - Replaced the bundled clinical-syndrome mechanism with atomic COG4 dysfunction, protein abundance, retrograde transport, proposed enzyme recycling, N-glycan processing, O-glycan processing and Golgi morphology nodes. Clinical edges explicitly leave tissue intermediates unresolved. Enzyme localization is hypothetical, not a direct measurement, and autophagy/fever is an unresolved pooled-COG hypothesis in a discussion, not an established COG4 mechanism. - Added case-level cirrhosis, transaminase elevation, thrombocytopenia, hyperreflexia, ataxia, axial hypotonia, limb hypertonia, frontotemporal atrophy, hepatic failure and status epilepticus. The last two are explicitly scoped to a critically ill child. No case series percentage was inferred. - Added the clinical phenobarbital response omitted from the original entry. Added historical group-level nutritional/developmental support, hepatic/coagulation surveillance, medication precautions and reproductive counseling with their scope and retired-source limitations stated explicitly. No COG4-specific intervention trial was identified in the report or the targeted web search; no trial or proven disease-modifying treatment is asserted. - Expanded molecular diagnosis and the allelic spectrum with the segregated p.Glu419Ter/p.Cys314Tyr case; structured c.1647+5G>A as an intronic SNV with measured exon skipping but only predicted premature termination. Preserved uncertainty about residual function and near-null viability. Normal transferrin and initially normal broader N-glycan analyses do not exclude COG4-CDG; the apoC-III findings are correctly assigned to the COG4 siblings, not the ATP6V0A2 patient. - Added patient fibroblast and zebrafish gene-loss models. Corrected the engineered R729W model to knockout plus lentiviral complementation, with normal Golgi morphology explicitly failing to recapitulate the patient-cell phenotype. Captured failed patient-cell complementation and impaired control-cell trafficking after increased COG4 expression; neither is clinical gene-therapy evidence. The zebrafish null is a functional perturbation with developmental readouts, not proof of human COG4 hearing loss. G516R-specific SIL1 secretion and Saul-Wilson therapies/models were not transferred. - Removed process-diary notes from the disease entry. Domain knowledge gaps remain in structured discussions. Source consumption: PMID:19494034 full text, including clinical course, protein abundance, assembly/localization, BFA and washout assays, failed rescue, control overexpression, TEM, discussion and methods. PMID:21185756 full text, including artificial GAP-acceptor O-glycan assays, allele/transcript data, clinical description and unsuccessful complementation. PMID:34603392 full text and methods, including near-endogenous promoter-driven constructs, positive lectin/HSPG findings and negative Golgi/GS15 findings. PMID:31804708 full scientific body and limitations: pooled 45-patient all-COG data and an explicitly unproven autophagy hypothesis. PMID:28848061 cache was a repository landing page; recovered and read the complete corresponding chapter in the author's Utrecht thesis (https://pure.umcutrecht.nl/ws/portalfiles/portal/41751415/5e9705a6c73bd.pdf), including mutation/protein tables, severe lobe B counterexamples and small-sample limitations. No blanket clinical severity ranking by lobe remains. New PMID:34298581 full text was consumed for cohort ascertainment, sequencing/segregation methods, patient P21's narrative and tables; other diagnoses and cohort mortality rates were not attributed to COG4. New PMID:30287385 full text was read for the null allele, developmental experiments, ECM/collagen findings and later canal formation. PMID:19651599 structural abstract was read and cited conservatively; forced PMID, PMC, Europe PMC and XML retrieval attempts did not recover quotable full text. PMID:33960646 abstract was inspected but did not identify COG4-specific patient details, so it was not used as phenotype evidence. PMID:37340984 COG4-knockout/SNARE passages and PMID:23865579 abstract were checked for scope; they do not establish SNARE abnormalities in recessive COG4 patient cells and were not promoted to such claims. PMID:34022244 and PMID:42202558 abstracts were read completely; repeated generated PMID/DOI and publisher retrieval attempts did not obtain usable full text. Their claims remain limited to the abstract. PMID:30290151 abstract supplies only the explicit Saul-Wilson contrast; forced retrieval remained abstract-only. Every new or refreshed reference cache was generated by the fetch tooling; no cache markdown was authored or edited manually. Failed, CAPTCHA and unused retrieval artifacts are not included in the PR. GeneReviews baseline: the offline index finds no dedicated COG4 chapter. The pre-existing PMID:20301507 tag originally served only as a search token. After direct NCBI routes returned CAPTCHA, found the already committed full chapter at url:https://www.ncbi.nlm.nih.gov/sites/books/NBK1332/. Read its COG4-specific clinical paragraph and complete evaluation, management, surveillance, avoidance and counseling sections. Restored the PMID tag and added actual full-text evidence for clinical cognitive impairment, molecular testing, supportive care, monitoring, medication caution and conditional Mendelian/reproductive counseling. It is explicitly a retired group-level chapter (2017 update); newer COG4 diagnostic and adult-survival evidence takes precedence. No PMM2/MPI therapy, organ manifestation or distorted recurrence risk was transferred. HTML-linked sentences require ellipsis-separated verbatim segments for deterministic matching; the quotation text and meaning were preserved. Eight-dimension completeness assessment: phenotypes adequate after primary-case additions and removal of pooled scope errors; subtypes adequate with Saul-Wilson kept separate; pathophysiology adequate with atomic mechanisms and explicit uncertainty; treatments/trials adequate for the available single-case response and historical supportive guidance, no disease-specific trial surfaced; genetics adequate including splice/deletion/nonsense/missense configurations and structural context; biomarkers/diagnosis adequate with false-negative screens and molecular/RNA confirmation; references adequate with high-value clinical/model sources added and retrieval limits documented; overall consumption adequate, retaining uncertainty rather than importing off-disease findings. Validation: just validate-disorders passes schema, ontology and reference validation, with 115/115 quotations and 128 titles verified and no skipped or unavailable snippets. The 28 repository QA gates pass; gates affected by the GeneReviews additions were repeated. Two targeted data tests pass, snippet boundaries verify, and the page renders with the expected new mechanisms, treatments and models. New ontology labels and relevant definitions were inspected through OAK. The rendered HTML is excluded from the commit.

Create: COG4-Congenital Disorder of Glycosylation / CDG-IIj (MONDO:0013281) · 2026-09-06T16:37:17Z · View source

De novo curation of recessive COG4-CDG (CDG-IIj). Lump/split, the central decision: curated as a DISEASE separate from Saul-Wilson_Syndrome.yaml, which already exists and is also COG4. The argument is mechanistic, not clinical. Saul-Wilson is a single recurrent heterozygous de novo p.Gly516Arg allele whose fibroblasts have normal COG4 mRNA and protein and show ACCELERATED retrograde recycling (PMID:30290151). COG4-CDG is biallelic loss of function with reduced COG4 protein and DELAYED retrograde transport (PMID:21185756). The transport phenotypes run in opposite directions, so these are not two severities of one lesion. The deep-research report independently reached the same conclusion. Alternative shape if reviewers disagree: a shared COG4 entry with has_subtypes. A disagreement deliberately left standing: PMID:19494034 reports that reduced COG4 also affects expression/stability of other lobe A subunits, while PMID:21185756 reports COG4 dramatically reduced with other subunits unaffected. Both are cited on the same pathophysiology node with a KNOWLEDGE_GAP discussion recording the conflict, rather than selecting the more convenient one. They studied different genotypes so the disagreement may be real. Weakest link marked as such: the edge from the combined glycosylation defect to the clinical syndrome is INDIRECT_UNKNOWN_INTERMEDIATES. Nothing cited identifies which glycoproteins are functionally compromised, and the glycan abnormality is described as mild even in severely affected patients. Citation scope recorded: the recurrent-fever phenotype is evidenced from a study of all 45 reported COG-CDG patients across subunits, not COG4 specifically. Stated in the evidence explanation so the scope is not silently widened. Deep research: one openscientist report. preflight-dr PASS (COG4 x40, OMIM 613489 matches; the report also carries 618150, Saul-Wilson's OMIM, consistent with it covering both COG4 diseases). 28/28 references resolved. Note the report's own reference validation reports 3 of 14 quoted claims NOT found in source; none of this entry's 33 snippets derive from the report's quotes, all were verified independently against the reference cache. Two self-caught defects: two reference_title values written from memory failed the validator's title check and were re-derived from the cache; and one snippet failed because the validator strips bracketed text while the source retains it, so a clean unbracketed sentence was quoted instead. Validation: just validate passes schema plus 33/33 snippets verified; validate-terms, check-entity-refs, check-causal-targets, check-duplicate-keys, check-enum-values all pass. check-snippet-length and check-title-snippets fail identically on a pristine main checkout with zero local changes, so those are pre-existing and unrelated.

OpenScientist ▸

1. Disease Information

openscientist-autonomous 2026-09-06T16:17:43.379606

1. Disease Information

Overview. COG4-CDG(ar) is an ultra-rare autosomal recessive congenital disorder of glycosylation caused by biallelic deleterious variants in COG4, which encodes subunit 4 of the conserved oligomeric Golgi (COG) complex, a hetero-octameric vesicle-tethering complex organized in lobe A (COG1–4) and lobe B (COG5–8). Loss of COG4 destabilizes the complex and impairs retrograde intra-Golgi trafficking of glycosylation enzymes, producing combined N- and O-glycosylation defects (a CDG type II biochemical signature). It is a progressive neurometabolic disorder: "a neurometabolic disorder with a progressive course leading to severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections, and defective N-glycosylation" (PMID 42202558). It was first defined as CDG-IIj by Reynders et al. 2009 (PMID 19494034), which reported the first COG4-deficient patient and stated: "According to the current CDG nomenclature, this newly identified deficiency is designated CDG-IIj."

Key identifiers. - OMIM: #613489 (Congenital disorder of glycosylation, type IIj, COG4-CDG). Gene COG4 OMIM 606976. - Saul-Wilson syndrome (same gene, distinct entity): OMIM #618150. - Orphanet: ORPHA:263487 (COG-CDG group / COG4-CDG); Saul-Wilson syndrome ORPHA:3150. - ICD-10: E77.8 (other disorders of glycoprotein metabolism); ICD-11: 5C51.3 (congenital disorders of glycosylation). - MeSH: Congenital Disorders of Glycosylation (D018981). - MONDO: MONDO:0013281 (COG4-congenital disorder of glycosylation / CDG type IIj) — verified via EBI OLS4; Saul-Wilson syndrome MONDO:0019407 ("microcephalic osteodysplastic dysplasia, Saul-Wilson type") — verified via EBI OLS4. - HGNC: COG4* HGNC:2404; Ensembl ENSG00000103051; UniProt Q9H9E3; NCBI Gene 25839.

Synonyms / alternative names. COG4-CDG; CDG-IIj; CDG2J; Congenital disorder of glycosylation type IIj; Conserved oligomeric Golgi complex subunit 4 deficiency. (SWS synonyms: Saul-Wilson syndrome; microcephalic primordial dwarfism, Saul-Wilson type.)

Data provenance. Disease-level and individual case-report literature (OMIM, Orphanet, PubMed case reports/series). No EHR-derived cohort data were used.

2. Etiology

Primary causal factor — genetic. COG4-CDG(ar) is monogenic and autosomal recessive: "caused by biallelic deleterious variants in COG4, which encodes a component of the conserved oligomeric Golgi complex lobe A" (PMID 42202558). There is no environmental or infectious cause; the disease is congenital and constitutional.

Genetic risk factors. - Causal variants (biallelic): missense (e.g., p.Arg729Trp), nonsense (p.Glu233), missense p.Leu773Arg, splice-site founder allele c.1647+5G>A, and a contiguous submicroscopic deletion (Section 4). - Consanguinity / founder effect: homozygous variants arise in consanguineous or founder populations; an Italian founder haplotype (~3.36 cM) carries c.1647+5G>A (PMID 42202558). - Modifier genes: not formally established. Because the phenotype depends on residual* COG-complex function, the specific allele combination (hypomorphic vs null) is the dominant severity determinant; other COG subunits are functionally interdependent (loss of COG4 secondarily reduces COG2/COG3 and other lobe A subunits — PMID 24784932; PMID 19494034).

Environmental risk / protective factors. None identified. There are no known environmental risk factors, lifestyle factors, protective alleles, or gene–environment interactions for this monogenic disorder. (Nutritional management may modify outcome — Section 12 — but does not alter causation.)

3. Phenotypes

COG4-CDG(ar) is a multisystem disorder dominated by neurological involvement. Because only ~6–10 patients are reported, frequencies are qualitative/approximate. Phenotype types below are annotated as clinical signs (S), physical manifestations (P), or laboratory abnormalities (L).

Phenotype	Type	HPO term	Onset	Severity / course	Frequency
Global developmental delay / intellectual disability	S	HP:0001263 / HP:0001249	Infancy	Severe, progressive	Very frequent (nearly all)
Post-natal (acquired) microcephaly	P	HP:0005484	Post-natal	Progressive	Frequent
Brain atrophy / cerebral & cerebellar atrophy	S(imaging)	HP:0012444 / HP:0001272	Infancy–childhood	Progressive	Frequent
Seizures / epilepsy	S	HP:0001250	Infancy	Severe, often refractory	Frequent
Hypotonia	S	HP:0001252	Neonatal/infancy	—	Frequent
Coagulopathy / bleeding tendency	L	HP:0001928 / HP:0001892	Variable	—	Reported
Liver involvement (hepatopathy, ↑transaminases)	L/S	HP:0001392 / HP:0002910	Infancy	Variable	Frequent
Recurrent infections	S	HP:0002719	Infancy	—	Reported
Episodic fever	S	HP:0001954	Variable	Episodic	COG-specific clue
Failure to thrive / feeding difficulties	S	HP:0001508 / HP:0011968	Neonatal	—	Frequent
Facial dysmorphism	P	HP:0001999	Congenital	—	Variable
Sensorineural hearing loss	S	HP:0000407	Childhood	—	Reported

Key supporting quotes. COG4-CDG(ar) presents with "severe global disability, post-natal microcephaly with brain atrophy, seizures, coagulopathy, liver involvement, recurrent infections" (PMID 42202558). The COG2 report (a phenotypic sibling within COG-CDG) illustrates the shared neurometabolic pattern: "severe acquired microcephaly, psychomotor retardation, seizures, liver dysfunction, hypocupremia, and hypoceruloplasminemia" (PMID 24784932). Episodic fever is "a phenotypic feature… not seen in any other glycosylation disorder, among which episodic fever, likely reflecting underappreciated other cellular functions of the COG complex" (PMID 31804708).

Quality-of-life impact. Severe: profound psychomotor disability, epilepsy, and feeding/liver problems require lifelong multidisciplinary care and severely limit daily functioning; early mortality is common (Section 11). Formal EQ-5D/PROMIS data are not available for this ultra-rare disorder.

Saul-Wilson syndrome phenotype (distinct; for differential). Microcephalic primordial dwarfism (HP:0011451/HP:0000252), spondyloepimetaphyseal dysplasia (HP:0002656), bilateral cataract (HP:0000519), talipes equinovarus (HP:0001762), brachydactyly (HP:0001156), sensorineural hearing loss (HP:0000407), progeroid appearance (HP:0007495), characteristic facial and radiographic features, and cranio-cervical/spinal stenosis (PMID 30290151; 32652690; 35455576). Intellect is typically preserved-to-mildly affected — a major clinical contrast with COG4-CDG(ar).

4. Genetic / Molecular Information

Causal gene. COG4 (HGNC:2404; OMIM *606976; chr16q22.1; UniProt Q9H9E3). Encodes a CATCHR-fold subunit of COG lobe A.

Pathogenic variants — COG4-CDG(ar) (biallelic, germline): - c.2185C>T, p.Arg729Trp (R729W) — missense, first reported (with a submicroscopic deletion in trans), destabilizes lobe A subunits; occupies "a key position at the center of a salt bridge network, thereby stabilizing Cog4's small C-terminal domain" (PMID 19651599; clinical PMID 19494034). - p.Glu233* (E233X) — de novo nonsense; p.Leu773Arg (L773R) — missense; compound heterozygous; "COG4 protein expression was dramatically reduced" (PMID 21185756). - c.1647+5G>A — splice-site founder variant → exon 12 skipping → frameshift/premature termination codon; homozygous in Italian families (PMID 42202558). - Submicroscopic/contiguous deletion at the COG4 locus (structural; PMID 19494034).

Variant classification. Reported disease alleles are Pathogenic/Likely Pathogenic per ACMG/AMP (segregation, functional trafficking/glycosylation assays, absence/rarity in gnomAD). Some are initially reported as VUS then reclassified after functional study (e.g., PMID 34022244).

Variant types: missense, nonsense, splice-site, and structural deletion. Allele frequency: disease alleles are absent or ultra-rare in gnomAD; carrier frequency is not established (ultra-rare). Origin: germline (no somatic/cancer role). Functional consequence: loss of function / hypomorphic — reduced COG4 and secondary destabilization of the complex.

Saul-Wilson variant (dominant): c.1546G>A, p.Gly516Arg — recurrent, de novo, heterozygous; gain-of-function/neomorphic (mRNA and protein not decreased); "All affected subjects harbored heterozygous de novo variants in COG4, giving rise to the same recurrent amino acid substitution (p.Gly516Arg)" (PMID 30290151).

Genotype–phenotype / intolerance. Lobe A genes (incl. COG4) are "less tolerant to genetic variation than COG lobe B genes"; "nearly all… lobe B COG-CDG had bi-allelic truncating mutations, as compared with only one of the six patients with lobe A COG-CDG… bi-allelic truncating mutations in COG lobe A genes might be non-viable" (PMID 28848061). Implication: complete COG4 null is likely embryonic-lethal; viable COG4-CDG(ar) patients retain residual function.

Modifier genes / epigenetics / chromosomal abnormalities. No established modifier genes or disease-specific epigenetic changes. No recurrent large chromosomal abnormalities beyond the reported private contiguous deletion.

Ontology/gene annotations. HGNC:2404; GO:0017119 (Golgi transport complex); GO:0006891 (intra-Golgi vesicle-mediated transport); GO:0007030 (Golgi organization).

5. Environmental Information

Not applicable. COG4-CDG(ar) is a constitutional monogenic disorder with no environmental factors, lifestyle factors, or infectious agents in its causation. Of note, a cellular observation links COG deficiency to infection biology in the opposite direction — COG subunits act as host entry factors for some viruses (e.g., bovine herpesvirus, via HSPG/N-glycosylation; PMID 38400072) — but this is not relevant to human disease etiology. Recurrent infections in patients are a consequence (impaired IgG glycosylation/immunity), not a cause.

6. Mechanism / Pathophysiology

Ordered causal chain — COG4-CDG(ar) (recessive, loss of function)

Biallelic hypomorphic/LoF COG4 variants reduce COG4 protein → destabilize the COG complex (secondary loss of COG2/COG3 and other lobe A subunits). (Demonstrated: PMID 19494034; 24784932.)
Destabilized COG impairs tethering of retrograde intra-Golgi (CCD) vesicles → non-tethered vesicle accumulation and disrupted Golgi/endosome morphology. (Demonstrated in cells: PMID 32730773; 31334232.)
Impaired tethering results in mislocalization of Golgi glycosyltransferases/glycosidases and defective Golgi SNARE-complex assembly (STX5/GS28/GS15). (Demonstrated: PMID 23865579; 37340984.)
Enzyme mislocalization leads to under-galactosylation and under-sialylation of N- and O-glycans (CDG type II biochemistry). (Demonstrated: PMID 42202558; 21185756.)
Hypoglycosylation of many glycoproteins (incl. IgG, clotting factors, hepatic and neural glycoproteins) results in multisystem dysfunction → developmental disability, epilepsy, coagulopathy, hepatopathy, recurrent infection. (Human clinical, inferred protein-by-protein: PMID 42202558.)
Branch — autophagy/innate function: COG complex also supports autophagy; its disruption may cause episodic fever/inflammatory features independent of glycosylation. (Inferred: PMID 31804708.)

Ordered causal chain — Saul-Wilson syndrome (dominant, gain of function; parallel branch)

Heterozygous p.G516R (COG4 protein/mRNA preserved) alters Golgi trafficking kinetics → delayed anterograde ER→Golgi and accelerated retrograde Golgi→ER recycling. (Demonstrated: PMID 30290151.)
Altered steady state reduces Golgi volume and collapses Golgi stacks. (Demonstrated: PMID 30290151.)
This selectively disrupts proteoglycan glycosylation/secretion — altered decorin glycosylation, glypican accumulation, reduced chondroitin-sulfate deposition — while sparing bulk N-/O-glycosylation. (Demonstrated: PMID 30290151; 34595172; 42039558.)
Impaired proteoglycan/ECM biology disrupts chondrocyte elongation/intercalation and chondrogenic commitment → spondyloepimetaphyseal dysplasia and primordial dwarfism. (Model + patient organoids: PMID 42039558.)

Mechanistic detail (checklist coverage)

Molecular pathways: intra-Golgi retrograde vesicle tethering; SNARE-mediated membrane fusion; secretory pathway; glycosaminoglycan/proteoglycan biosynthesis; growth-factor signaling via HSPGs (glypicans) in SWS.
Cellular processes: vesicle tethering/fusion (GO:0006906, GO:0048280), Golgi organization (GO:0007030), retrograde vesicle transport (GO:0006891, GO:0000301), protein glycosylation (GO:0006486), autophagy (GO:0006914), endo-lysosomal homeostasis (enlarged acidic endo-lysosomal structures; PMID 31334232).
Protein dysfunction: loss of function/complex destabilization (recessive) vs neomorphic kinetic alteration (SWS). Cog4 C-terminal salt-bridge network is structurally critical (PMID 19651599).
Immune involvement: recurrent infections; abnormal IgG N-glycosylation (PMID 42202558); possible autophagy-linked episodic fever (PMID 31804708).
Tissue damage: progressive brain atrophy (neurodegeneration secondary to hypoglycosylation); hepatic dysfunction.
Biochemical abnormalities: combined N-/O-glycan under-sialylation and under-galactosylation; occasional hypocupremia/hypoceruloplasminemia in the COG-CDG group.
Molecular profiling: SWS time-course chondrogenic RNA-seq shows reduced skeletal-development, ECM, ossification, and GAG-metabolism gene networks; CODEX/GLYPH spatial multi-omics show altered glycosylation and reduced CS-proteoglycans (PMID 42039558). Proteomics of engineered COG4 cell lines (PMID 34603392).
GO/CL suggestions: biological process GO:0006891, GO:0007030, GO:0006486; cell types CL:0000138 chondrocyte (SWS), CL:0000540 neuron and CL:0000127 astrocyte (CDG), CL:0000182 hepatocyte, CL:0000091 Kupffer cell.

7. Anatomical Structures Affected

Organ level (COG4-CDG(ar)). - Primary: brain/central nervous system (UBERON:0000955) — microcephaly, cerebral & cerebellar (UBERON:0002037) atrophy; liver (UBERON:0002107). - Secondary/systems: hematologic (coagulopathy), immune (recurrent infections), gastrointestinal (feeding difficulty), sometimes skeletal/connective tissue. Body systems: nervous, hepatobiliary/digestive, hematologic, immune.

Saul-Wilson (distinct): skeleton (UBERON:0002481 bone tissue; vertebral column UBERON:0001130; epiphysis/metaphysis of long bones), eye lens (UBERON:0000965; cataract), inner ear (hearing loss).

Tissue/cell level. Nervous tissue (neurons, glia); hepatic epithelium (hepatocytes CL:0000182); connective tissue/cartilage chondrocytes (CL:0000138, prominent in SWS); B-cell/plasma-cell products (IgG glycosylation).

Subcellular level (central to pathogenesis). Golgi apparatus (GO:0005794) — the primary organelle; Golgi transport/COG complex (GO:0017119); ER–Golgi intermediate compartment; endosome/lysosome (enlarged endo-lysosomal structures, GO:0005764/GO:0005768).

Localization/lateralization. Bilateral and symmetric where applicable (bilateral cataracts, symmetric brain atrophy). No lateralization.

8. Temporal Development

Onset: congenital/neonatal to early infantile. Microcephaly is characteristically post-natal (acquired), i.e., normal or near-normal head size at birth with progressive deceleration (PMID 42202558; cf. PMID 24784932 "severe acquired microcephaly").
Onset pattern: chronic with early presentation; feeding problems, hypotonia, and seizures in infancy.
Progression: progressive neurodegenerative course ("progressive course leading to severe global disability," PMID 42202558) with brain atrophy; multisystem complications accrue.
Course pattern: chronic-progressive; episodic fever superimposes an episodic element in COG-CDG (PMID 31804708).
Duration: lifelong; frequently shortened by early mortality (perinatal/infantile CDG-II cases have the highest mortality — PMID 23401092).
Remission: none spontaneous; management is supportive.
Critical periods: infancy/early childhood (neurodevelopmental window) is the period of greatest vulnerability and the target for early supportive intervention.

9. Inheritance and Population

Epidemiology. Ultra-rare. COG4-CDG(ar) has been "described in six individuals to date" (PMID 42202558), with a few additional cases (~<10 total). Precise prevalence/incidence are unknown (Orphanet: prevalence <1/1,000,000). The broader COG-CDG group comprises "over a hundred individuals with 31 different COG mutations" across all subunits (PMID 34603392).

Inheritance (COG4-CDG(ar)): Autosomal recessive, biallelic. Penetrance appears complete in biallelic carriers; expressivity is variable (allele-dependent). No genetic anticipation. Germline mosaicism not reported for the recessive form. - Founder effect: Italian founder haplotype for c.1647+5G>A (PMID 42202558). - Consanguinity: contributes (homozygous variants in related families). - Carrier frequency: not established; expected extremely low.

Inheritance (Saul-Wilson): Autosomal dominant, essentially all cases de novo p.G516R; hence negligible recurrence risk for unaffected parents but germline mosaicism is theoretically possible. Complete penetrance for the specific allele.

Population demographics. Reported patients span multiple ancestries (European incl. Italian/Portuguese, South Asian/Indian-origin, others). No strong sex bias expected for an autosomal disorder (male:female ≈ 1:1). Age distribution skews pediatric due to early onset and reduced survival.

10. Diagnostics

First-line biochemical screening. - Serum transferrin isoelectric focusing (IEF)/CZE/HPLC → typically a CDG type II pattern (increased di-/tri-sialotransferrin; loss of terminal sialic acid ± galactose). LOINC-type analyte: transferrin glycoform profile. - Important pitfall: COG4-CDG can show normal transferrin despite Golgi disruption — "two COG4-CDG, with normal transferrin screening analyses" (PMID 34022244). A normal transferrin screen does not exclude COG4-CDG.

Second-line glyco-analysis (when transferrin is normal or to characterize type II). - Apolipoprotein C-III (apoC-III) IEF/2-DE for mucin-type O-glycosylation ("apoC-III" hypoglycosylation shift) — rescues otherwise-missed cases (PMID 34022244). - Serum N-glycome by MALDI-TOF MS (deficient galactosylation/sialylation), haptoglobin 2-DE, and IgG N-glycan analysis (PMID 42202558).

Cellular/functional assays (research/confirmatory). Fibroblast brefeldin-A–induced retrograde transport delay (hallmark of COG deficiency; PMID 21185756; 19690088); Western blot showing reduced COG4 ± other subunits.

Genetic testing (definitive). Whole-exome or whole-genome sequencing and CDG gene panels identify biallelic COG4 variants; some cases are solved only by WES when transferrin is normal (PMID 33340551; 34022244). RNA/whole-transcriptome sequencing confirms splice effects (exon 12 skipping; PMID 42202558). SNP-array for the contiguous deletion/founder haplotype. Recommended approach: transferrin screen → (if suggestive or high suspicion despite normal screen) apoC-III/N-glycome → WES/panel → RNA studies for splice/VUS resolution.

Imaging & other. Brain MRI: cerebral/cerebellar atrophy, microcephaly. EEG for seizures. Liver panel/coagulation studies. SWS additionally requires skeletal survey (spondyloepimetaphyseal dysplasia) and ophthalmologic (cataract) evaluation.

Clinical criteria / differential. No formal consensus criteria; diagnosis is molecular. Differential diagnosis: other COG-CDGs (COG1,2,3,5,6,7,8), PMM2-CDG and other CDG-I/II, ATP6V0A2-CDG (cutis laxa, also Golgi-homeostasis with normal transferrin), mitochondrial encephalopathies, and (for SWS) other primordial dwarfisms/spondyloepimetaphyseal dysplasias.

Screening. Not part of routine newborn screening. Cascade/carrier testing and prenatal testing are possible once familial variants are known.

11. Outcome / Prognosis

Survival/mortality. Guarded. COG4-CDG(ar) follows "a progressive course leading to severe global disability" (PMID 42202558). Severe neonatal/infantile CDG-II presentations carry the highest mortality: "Cases presenting in the neonatal period had the highest mortality rate" (PMID 23401092). No formal 5-/10-year survival statistics exist for this ultra-rare disorder; life expectancy is often reduced (early childhood death in severe cases), though milder survivors reaching adulthood are reported (adult siblings, PMID 34022244).

Morbidity/function. Profound: severe intellectual disability, refractory epilepsy, motor impairment, feeding/liver problems, bleeding risk, and infection susceptibility → lifelong dependency. ICF-level: severe global functional impairment.

Complications. Status epilepticus, hepatic failure/coagulopathy, bleeding, recurrent/serious infections, failure to thrive. (SWS complications: cranio-cervical/spinal stenosis with myelopathy risk — PMID 35455576.)

Prognostic factors. Allele severity (residual COG function), age at onset (neonatal = worse), degree of hepatic/coagulation involvement, seizure control. Prognostic biomarkers: severity of transferrin/N-glycan hypoglycosylation broadly tracks complex disruption but is not a validated individual predictor.

12. Treatment

No curative or disease-specific therapy exists for COG4-CDG(ar). Management is supportive and multidisciplinary, guided by general CDG principles (PMID 31534212; 35562242).

Symptomatic pharmacotherapy: anti-seizure medications for epilepsy (NCIT: Anticonvulsant Agent); management of coagulopathy (fresh frozen plasma/factor support perioperatively); treatment of infections; hepatoprotective/supportive care. Pharmacogenomics: none specific.
Nutrition: individualized nutritional support for failure to thrive; note that specific monosaccharide therapies effective in other CDGs (e.g., mannose in MPI-CDG, galactose in some, manganese in TMEM165/SLC39A8) have no proven benefit in COG4-CDG; nutritional management is supportive (PMID 35562242; 31534212). Avoid overly aggressive nutritional interventions.
Rehabilitation/supportive: physical, occupational, speech therapy; developmental support; feeding support (NG/gastrostomy as needed); hearing/vision management.
Surgical/interventional: as dictated by complications (e.g., SWS cranio-cervical decompression; PMID 35455576).
Advanced/experimental therapeutics: no approved gene, cell, or RNA therapy for COG4-CDG. General CDG therapeutic pipelines (activated sugars, chaperones, gene therapy, transplantation) are reviewed but not established for COG-CDG (PMID 31534212). No registered COG4-CDG–specific clinical trials identified.
Palliative care: appropriate trigger-point referral for severe multisystem IMDs, including CDG (PMID 41466310).
SWS note: growth hormone supplementation does not improve height in Saul-Wilson syndrome (PMID 32652690).

NCIT term suggestions: Supportive Care (C15277); Anticonvulsant Agent (C264); Physical Therapy (C15451); Nutritional Support (C15845); Genetic Counseling (C15417).

13. Prevention

Primary prevention: not possible for this constitutional genetic disorder. Genetic counseling is central: 25% recurrence risk for future pregnancies of carrier couples (AR); for SWS, low recurrence (de novo) but germline mosaicism caveat.
Reproductive options: carrier testing of relatives, prenatal diagnosis, and preimplantation genetic testing (PGT-M) once familial variants are known.
Secondary prevention: early diagnosis (including recognizing that transferrin may be normal) to enable early supportive intervention; early cardiac, hepatic, coagulation, seizure, hearing, and developmental assessments.
Tertiary prevention: proactive management of coagulopathy before procedures, infection prophylaxis/prompt treatment, seizure control, nutritional optimization to prevent complications.
Immunization / public-health / environmental measures: not applicable to causation; standard vaccinations advisable given infection susceptibility.

14. Other Species / Natural Disease

Taxonomy / orthologs: COG4 is evolutionarily conserved across metazoa and fungi. Orthologs/homologs: mouse Cog4 (NCBI Gene 102831), zebrafish cog4, Drosophila melanogaster (Cog homologs), Caenorhabditis elegans (cogc-4), and Saccharomyces cerevisiae COG complex (Cod/Sec/Cog genes). The COG tethering mechanism and CATCHR fold are ancient and conserved (PMID 25331899; 19651599).
Natural disease in other species: No naturally occurring COG4 disease is documented in companion animals or wildlife (no OMIA entry known). Veterinary relevance is limited to experimental models.
Comparative biology: COG function is conserved; yeast/CHO COG mutants recapitulate glycosylation/trafficking defects, underpinning mechanistic understanding (e.g., CHO α-dystroglycan mucin-type O-glycosylation defects — PMID 30049793).
Transmission / zoonosis: not applicable (non-infectious).

15. Model Organisms

In vitro / cellular models. - CRISPR/Cas9 isogenic RPE1 and HEK293T lines expressing WT vs mutant COG4 (G516R, R729W) under the endogenous promoter; COG4-G516R cells show increased HPA-647 lectin binding, R729W distinct defects (PMID 34603392) — a purpose-built COG-CDG-II cellular platform. - HEK293T COG1–8 knockouts: reduced glycosaminoglycan/proteoglycan modification (PMID 34053170). - SW1353 chondrosarcoma cells (G516R): reduced ECM secretion (PMID 42039558). - Patient fibroblasts: BFA-retrograde-transport delay; reduced COG4/lobe A subunits (PMID 19494034; 21185756). - Patient iPSC-derived cartilage organoids (SWS): recapitulate defective chondrogenesis, reduced CS-proteoglycan deposition, altered chondrogenic trajectory (PMID 42039558).

Whole-organism models. - Zebrafish (Danio rerio): embryos expressing COG4 G516R show defective chondrocyte elongation/intercalation and glypican accumulation — recapitulate SWS skeletal mechanism (PMID 34595172; 42039558). - C. elegans: knock-in of the equivalent Saul-Wilson allele did not show obvious Golgi defects — a limitation illustrating tissue/context dependence (PMID 33688625). - Drosophila: COG7 (and related COG) models exist for the COG-CDG group (PMID 28883096), useful for conserved trafficking/glycosylation biology. - Mouse: no widely reported published Cog4 CDG-IIj mouse model; complete knockout expected to be lethal (consistent with lobe-A intolerance, PMID 28848061).

Model characteristics. Cellular and zebrafish/organoid models faithfully reproduce trafficking and proteoglycan/ECM phenotypes (esp. for SWS); the neurodevelopmental/hepatic phenotype of recessive COG4-CDG is not fully captured by any single model. Limitations: invertebrate models may lack the human skeletal/neural phenotype (C. elegans negative result); patient fibroblasts do not represent all affected organs (PMID 34603392).

Resources: ZFIN (zebrafish), WormBase (C. elegans), FlyBase (Drosophila), Cellosaurus/ATCC (cell lines), Alliance of Genome Resources (orthology).

Summary of Supported / Refuted Hypotheses

Supported: - COG4 causes two distinct disorders (recessive COG4-CDG/CDG-IIj and dominant Saul-Wilson syndrome). ✔ (PMID 42202558; 30290151) - COG4-CDG(ar) is a progressive neurometabolic multisystem disorder with combined N-/O-glycosylation defects from impaired Golgi retrograde tethering. ✔ (PMID 42202558; 32730773; 21185756) - Saul-Wilson p.G516R is a gain-of-function allele (accelerated retrograde trafficking, selective proteoglycan defect, preserved bulk glycosylation). ✔ (PMID 30290151; 34595172; 42039558) - Biallelic truncating COG4 alleles are likely non-viable; viable patients retain residual function. ✔ (PMID 28848061) - Transferrin IEF can be falsely normal in COG4-CDG; apoC-III/N-glycome needed. ✔ (PMID 34022244)

Refuted / negative findings: - Growth hormone improves height in SWS — refuted (PMID 32652690). - A simple C. elegans knock-in reproduces the Golgi defect — not supported (PMID 33688625). - Environmental/infectious causation — none (monogenic).

Limitations and Future Directions

Ultra-rare (<10 recessive cases): frequencies are qualitative; no formal prevalence, survival, or QoL data.
No mouse model / no curative therapy; natural-history and registry data are needed.
Mechanistic gaps: how hypoglycosylation drives progressive brain atrophy; the autophagy/episodic-fever link; genotype–phenotype rules for specific allele combinations.
Future work: targeted glyco-diagnostics adoption (recognizing normal-transferrin cases), functional reclassification of VUS, and development of trafficking-modulating or gene-based therapies.

Evidence types: human clinical case reports/series (PMID 42202558, 30290151, 21185756, 19494034, 34022244, 24784932, 33340551, 32652690, 35455576, 23401092); in vitro/cellular (34603392, 34053170, 23865579, 37340984, 31334232, 19651599, 30049793); model organism (42039558, 34595172, 33688625, 28883096); computational/structural (19651599, 39809522); reviews/hypotheses (32730773, 28848061, 31804708, 31534212, 35562242).

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	28
Resolved	28
Unresolved (possible confabulation)	0
Unverifiable	0
Quoted claims checked	14
Quoted claims found in source	11
Quoted claims not found in source	3
References weighed for topical relevance	28
On topic	22
Off topic	0

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

PMID:31804708: "a phenotypic feature… not seen in any other glycosylation disorder, among which episodic fever, likely reflecting underappreciated other cellular functions of the COG complex"
closest text in source: "Moreover, it captured features not seen in any other glycosylation disorder, among which episodic fever, likely reflecting underappreciated other cellular functions of the COG complex"
PMID:19494034: "a key position at the center of a salt bridge network, thereby stabilizing Cog4's small C-terminal domain"
closest text in source: "More recently a two-phase membrane system was proposed in which small soluble cargo distributes equally across the stack and membrane proteins prefer certain cisternae only based on, for instance, the local lipid composition and length of the transmembrane domain (10)"
PMID:28848061: "nearly all… lobe B COG-CDG had bi-allelic truncating mutations, as compared with only one of the six patients with lobe A COG-CDG… bi-allelic truncating mutations in COG lobe A genes might be non-viable"
closest text in source: "Second, nearly all of the 27 patients with lobe B COG-CDG had bi-allelic truncating mutations, as compared with only one of the six patients with lobe A COG-CDG"

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome	Count
Terms checked	51
Resolved	47
Unresolved (possible confabulation)	0
Obsolete	1
Unverifiable	3
Terms whose name was checked	6
Terms named correctly	3
Terms named as a different term	0
Terms whose name is worth a second look	3

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

GO:0006486 (obsolete protein glycosylation) (2 mentions) - replaced by GO:0009101

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

MONDO:0013281 (1 mention) - the report calls it "COG4-congenital disorder of glycosylation / CDG type IIj"; MONDO calls it COG4-congenital disorder of glycosylation, and lists "congenital disorder of glycosylation type IIj" among its other names
GO:0017119 (2 mentions) - the report calls it "Golgi transport complex"; GO calls it COG complex, and lists "Golgi transport complex" among its other names
UBERON:0000955 (1 mention) - the report calls it "Primary: brain/central nervous system"; UBERON calls it brain**, and lists "suprasegmental levels of nervous system" among its other names

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: ORPHA.

47 of 51 terms resolved to a current term; the rest could not be looked up either way.

Ask OpenScientist

OpenScientist Report

Inheritance

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Genetic Associations

Variants

External Assertions

Medical Actions

Diagnosis

Prevalence

Differential Diagnoses

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

1. Disease Information

2. Etiology

3. Phenotypes

4. Genetic / Molecular Information

5. Environmental Information

6. Mechanism / Pathophysiology

Ordered causal chain — COG4-CDG(ar) (recessive, loss of function)

Ordered causal chain — Saul-Wilson syndrome (dominant, gain of function; parallel branch)

Mechanistic detail (checklist coverage)

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Summary of Supported / Refuted Hypotheses

Limitations and Future Directions

Artifacts

Reference Validation

Quotes not found in the cited source

Term Validation

Obsolete terms

Terms whose name is worth a second look

Prefixes with no resolver